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This dissertation describes advances in the development of peptide-based methods for 
assembling nanomaterials. The aim of my work is four-fold: 1) develop methods to rationally 
tune the metrics of gold nanoparticle superstructures; 2) develop approaches to post-synthetically 
modify and stabilize gold nanoparticle superstructures; 3) develop an understanding of the 
underlying peptide assembly scaffold and how it dictates the final nanoparticle assembly 
architecture; and 4) develop new hybrid materials with peptide conjugate molecules having 
programmable R-groups. 
Specifically, in Chapter 2 I describe methods to tune the assembly of double-helical gold 
nanoparticle superstructures by modulating the sterics and hydrophobicity of a family of new 
peptide conjugate molecules. I show that I can tune the assembly metrics of doubles helices 
including pitch, nanoparticle size, and interhelical distance. Chapter 3 describes the construction 
of single-helical gold nanoparticle superstructures that exhibit intense chiroptical activity. I 
examine their underlying peptide assembly structure and arrive at a molecular-level 
understanding of their assembly and how it relates to the chiral nanoparticle superstructure. In 
Chapter 4, I demonstrate a straightforward approach to rationally tune the metrics of hollow 
spherical gold nanoparticle superstructures including nanoparticle coverage density and sphere 
diameters. I further demonstrate that their assembly can be stabilized post-synthetically via 
ligand exchange. Finally, in Chapter 5 I design new peptide conjugate building blocks composed 
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 v 
of peptides and oligonucleotides interlinked by a hydrophobic organic core. I outline design rules 
that govern their assembly and show that their assembly morphology can be rationally predicted 
and altered. 
 vi 
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1.0  INTRODUCTION 
1.1 SELF-ASSEMBLY IN NATURE 
Humans have long been fascinated with and inspired by the natural world. The beauty and 
complexity found in nature have been resources mined throughout history for knowledge and 
understanding in every aspect of life and remain a source of inspiration for future transformative 
ideas and innovations. A variety of fields, such as the visual arts, architecture, engineering, and 
chemistry, would not be where they are today without their respective contributors seeking 
vision and insight from the natural world around them. Recently, within the realm of materials 
science and chemistry, the natural process of molecular self-assembly – ubiquitous in nature – 
has transformed how scientists in these fields contemplate the design and construction of new 
materials.  
 Molecular self-assembly is the spontaneous self-organization of individual molecules into 
hierarchical structures. These structures are assembled primarily through non-covalent 
interactions such as van der Waals forces, electrostatic interactions, and hydrogen-bonding. 
Nature provides countless examples of self-assembled systems that display exquisite properties 
and function. Amazingly, these complex structures are assembled using simple biomolecules. A 
prime example are proteins. Proteins are composed of amino acid residues connected via amide 
bond linkages (polypeptide chain). The amino acids that constitute the polypeptide chain encode 
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Figure 1.1. Several different natural supramolecular protein assemblies. Ring proteins: (a) the β-clamp of E. coli 
(PDB:2POL); (b) the proliferating cell nuclear antigen PCNA of H. sapiens (PDB:1AXC); (c) bacteriophage T7 gp4 
helicase (PDB:1E0K); (d) bacteriophage λ exonuclease (PDB: 1AVQ); (e) TRAP (PDB: 1QAW); (f) RAD52 (PDB: 
1KN0). Non-covalent catenane proteins: (a) RecR (PDB: 1VDD); (b) Cys168Ser variant of Prx III (PDB: 1ZYE); 
(c) class 1a RNR (PDB: 4ERP); (d) CS2 hydrolase (PDB:3TEO). Tubular protein assemblies: (k) TMV (PDB: 
4UDV). (l) α-hemolysin pore complex (PDB: 7AHL); (m) anthrax protective antigen pore (PDB: 3J9C); (n) 
PhiX174 bacteriophage tail (PDB: 4JPP); (o) Hcp1 from P. aeruginosa (PDB: 1Y12). Protein cages: (a) maxi-
ferritin (PDB: 1BFR); (q) mini-ferritin (PDB:1DPS); (r) superimposition of ribbon structures of mini-ferritin (light) 
and maxi-ferritin (dark); (s) a surface view of the rat vault shell (PDB: 4HL8); (t) ribbon structure of the major vault 
protein monomer, showing the structural repeat domains (green), the shoulder domain (blue), the cap-helix domain 
(red), and the cap-ring domain (magenta); (u) surface-structure of triskelion and zoom showing the α-helical zigzags 
(PDB: 1XI4); (v) structure of hexagonal barrel. (All figures adapted from ref. 1) 
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the intricate folding information that directs their assembly into stable, functional 3D protein 
architectures. These defined protein architectures then serve to perform a variety of complex 
tasks, as observed in biology. Figure 1.1 presents several diverse supramolecular protein 
assemblies found in nature, highlighting the immense potential of simple biomolecules (e.g., 
amino acids) as building blocks for the design and construction of intricate, complex 
nanomaterials.1  
1.2 SELF-ASSEMBLY OF METALLIC NANOPARTICLES 
Motivated by the complex and functional assemblies derived from biological building blocks, 
scientists have begun exploiting biomolecules for the design and fabrication of a diverse array of 
novel synthetic materials. In the context of this dissertation, I will focus on the assembly of 
metallic nanoparticles into hierarchical superstructures. These novel hybrid materials have 
received significant interest due to their unique and exceptional properties.  
1.2.1 Properties of metallic nanoparticles and their assemblies 
Nanoparticles are classified as having at least one dimension between 1 and 100 nm. In this 
nanosized-regime, new properties emerge which are not observed for their bulk counterparts. 
This is especially evident with metallic nanoparticles. Metal nanoparticles exhibit unique size-, 
shape-, and composition-dependent properties which make them attractive candidates as building 
blocks for the fabrication of new materials. The optical properties of metal nanoparticles have 
been heavily studied and will be a focus of some of my work presented in this dissertation. Metal 
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nanoparticles, such as gold and silver nanoparticles, are characterized by their localized surface 
plasmon resonance (LSPR).2 LSPR is the resonant oscillation of conduction band electrons of 
metal nanoparticles in the presence of an electromagnetic field. The frequency at which the 
electrons resonate can directly be observed by their absorption at that corresponding wavelength. 
This LSPR absorption band is highly dependent on the physical shape of the particle, their 
passivating ligands, and their composition. For example, the LSPR band of gold nanorods can be 
tuned from the visible to the near-infrared (NIR) simply by adjusting their aspect ratio (Figure 
1.2).3  
 
 
Figure 1.2. Tunable optical properties of gold nanorods by changing their aspect ratios. (a) Gold nanorods of 
different aspect ratios exhibit different dimensions as observed by TEM. (b) Different colors and (c) different LSPR 
wavelengths associated with colloidal solutions of nanorods of different aspect ratios. (Adapted from ref. 3) 
 
In addition to their size-, shape-, and composition-dependent properties, metallic 
nanoparticles also exhibit ensemble properties when assembled together. For example, dispersed 
 5 
and aggregated gold nanoparticles display different optical properties. 15 nm gold particles 
exhibit an LSPR band at approximately 520 nm. This absorption in the blue-green region of the 
visible spectrum gives rise to the deep red color that is observed when these particles are 
suspended in solution. However, under conditions that cause aggregation, a purple colored 
solution is observed, signifying a red-shift of the LSPR absorption band. This arises due to the 
plasmonic coupling between neighboring nanoparticles, where the conduction electrons of 
particles in close proximity oscillate in unison, thereby shifting the LSPR band to longer 
absorption wavelengths. 
Based on the unique, tunable properties of metal nanoparticle-based assemblies, these 
materials have found applications as optical sensors,4-6 surface-enhanced Raman spectroscopy 
(SERS) substrates,7-10 heterogenous catalysts,11 therapeutic agents,8, 12-13 ‘plasmon rulers’,14-15 
and as components in optoelectronic and metamaterial devices.16-17 Current work in this field is 
focused on developing methods to rationally arrange nanoparticles into desirable architectures to 
precisely engineer and optimize their properties. 
1.2.2 Biomolecule-directed assembly of metallic nanoparticles 
Taking advantage of the intrinsic assembly properties of biomolecules, researchers have 
employed several different biomolecular building blocks, such as nucleic acids,16, 18-24 
peptides,25-30 proteins,31-34 and viruses,35-37 for directing the ‘bottom-up’ construction of metallic 
nanoparticles. The unique programmability of biomolecules allows for rational design of 
assembly architectures and systematic construction of materials with tunable morphologies and 
properties. 
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A few examples of biomolecule-directed assembly of metallic nanoparticles are shown in 
Figure 1.3. Recently, the Mirkin group pioneered DNA-based assembly methods of metallic 
nanoparticles into 3D crystalline nanoparticle superlattices (Figure 1.3a).21-22 Their method takes 
advantage of the programmable base-pairing interactions between complementary DNA-
functionalized nanoparticles. Under thermodynamic control, they show that they can program the 
assembly of metallic nanoparticles into a variety of different periodic lattices.21-22 In addition to 
DNA, viruses and proteins have also been utilized as assembly scaffolds and directing agents for 
assembling nanoparticles. (Figure 1.3b,c).  
 
 
Figure 1.3. Examples of biomolecule-directed assemblies of metallic nanoparticles. (a) 3D crystalline nanoparticle 
superlattices assembled from DNA-functionalized nanoparticles (adapted from ref. 22). (b) Gold nanoparticles 
decorated onto a tobacco mosaic virus scaffold (adapted from ref. 36). (c) End-to-end assembly of gold nanorods 
using streptavidin/biotin linkages (adapted from ref. 34). 
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1.3 PEPTIDE-BASED METHOD FOR ASSEMBLING NANOPARTICLE 
SUPERSTRUCTURES 
Over the past decade, the Rosi group has developed a peptide-based approach for assembling 
nanoparticles into complex and tunable architectures. The methodology centers around the 
distinctive capabilities of peptide-based molecules and provides a route for designing and 
assembling nanoparticles into intricate architectures. 
1.3.1 Assembly and substrate-binding properties of peptides 
Peptide self-assembly is promoted by a variety of non-covalent interactions including hydrogen 
bonding, electrostatics, van der Waals forces, hydrophobic interactions, and π-π stacking. Based 
on the amino acid sequence of the polypeptide chain, these non-covalent interactions can drive 
the assembly of peptide molecules into various secondary structures such as α-helices and β-
sheets. In addition to the amino acid sequence itself, moieties that provide additional assembly 
properties can be attached to the N- and C-termini to generate ‘peptide conjugates’. Peptide 
conjugates often consist of a peptide linked to a hydrophobic group (e.g., aliphatic chain); such 
peptide conjugates are designed to mimic the assembly properties of amphiphilic peptides. 
Figure 1.4 shows several different peptide-based structures with different morphologies that 
were assembled using peptides and peptide conjugates including nanotubes,38-39 helical fibers,40-
41 spherical structures,42-44 and nanosheets.45-47 
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Figure 1.4. Various structures assembled from peptides and peptide conjugates. (a) AFM images of KFE8 helical 
assemblies in aqueous solution (adapted from ref. 41). (b) TEM image of vesicles assembled from BP-A2-PEPAu (BP 
= biphenyl, A = alanine) (adapted from ref. 59). (c) TEM and SEM (inset) image of nanotubes assembled from N-
lauroyl-Aβ(16-22) assembled in 40% CH3CN/water with 0.1% trifluoracetic acid for 1-2 weeks (adapted from ref. 
38). (d) Assembly scheme and TEM image of nanosheets assembled from alpha-helical peptides (scale bar = 200 
nm; adapted from ref. 45).  
 
An important feature of peptide-based materials is the ability to tune their morphology 
and assembly metrics by manipulating their primary sequence. Drawing from the chemically 
diverse set of amino acid residues, researchers can rationally assemble peptide constructs into 
materials with programmable physical, mechanical, and chemical properties. Cui et al. recently 
demonstrated the effect of amino acid sequence on the assembly of 1D nanostructures of four 
constitutionally isomeric tetrapeptide amphiphiles (Figure 1.5a).48 They showed that they could 
tune the morphology and mechanical properties of 1D assemblies by changing the placement of 
E and V residues within the tetrapeptide (Figure 1.5b-d). For example, they determined that 
VVEE peptide conjugates assemble into rigid cylindrical fibers, whereas EVEV peptide 
conjugates assemble into flexible twisted nanoribbons (Figure 1.5c,d, respectively). Their results 
highlight the sequence-dependent properties of peptide-based materials and how simple 
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modifications to the peptide sequence can have a profound impact on their morphology and 
mechanical properties.  
 
 
Figure 1.5. (a) Molecular structures and schematic representation of isomeric peptide amphiphiles. (b-e) Cryo-TEM 
images of a variety of 1D nanostructures formed by the designed peptides in water after 2 weeks of incubation at 
room temperature: (b) nanobelts of VEVE; (c) rigid cylindrical nanofibers of VVEE; (d) twisted nanoribbons of 
EVEV; and (e) flexible and entangled nanofibers of EEVV. (Adapted from ref. 48) 
 
In addition to their intrinsic self-assembly capabilities, peptides also exhibit substrate 
recognition capabilities. Synthetic peptides can selectively recognize and bind biological 
substrates,49-51 graphene,52-53 and inorganic surfaces.54-56 Chiu and co-workers elegantly 
demonstrated the binding capabilities of two platinum-binding peptides, T7 (TLTTLTN) and S7 
(SSFPGPN), for directing the shape-controlled nanocrystal synthesis of platinum nanoparticles 
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(Figure 1.6).56 Using phage display, T7 and S7 were identified for their preferential binding onto 
the [100] and [111] facets of platinum, respectively. They then showed that reduction of 
platinum in the presence of T7 or S7 directed the growth of nanocrystals into Pt nanocubes or Pt 
tetrahedra, respectively. 
 
 
Figure 1.6. Biomimetic approach to the predictable synthesis of shaped nanocrystals. (a) Schematic illustration of 
face-specific peptide sequence selection and nanocrystal synthesis: Pt-[100] binding peptide sequence T7 and Pt-
[111] binding peptide sequence S7 are selected against [100] faceted and [111] faceted substrates; (b) facet-specific 
peptides are used to direct the synthesis of platinum nanocrystal cubes and tetrahedra, respectively. (c) TEM images 
(scale bar = 20 nm) of platinum nanocrystals obtained in the presence of (c) T7, (d) S7, and (e) BP7A (a peptide 
previously selected against bulk platinum polycrystalline surfaces). (f) TEM image (scale bar = 20 nm) of platinum 
nanocrystals obtained in the absence of peptides. All samples were conducted under the same conditions and 
collected after reacting for 10 min. (Adapted from ref. 56) 
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1.3.2 Methodology background 
Exploiting both the self-assembling and inorganic-binding properties of peptides, the Rosi group 
has developed peptide-based methods for constructing ordered nanoparticle superstructures 
having tunable structures and properties.11, 25, 57-65 This method was first successfully realized in 
2008, when Chen et al. employed a gold-binding peptide conjugate, C12-PEPAu (C12 = 12-carbon 
aliphatic group, PEPAu = AYSSGAPPMPPF55), to direct the assembly of gold nanoparticles.25 
They demonstrated that in the presence of a gold precursor (chloroauric acid, HAuCl4) and 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, C12-PEPAu both binds to and 
directs the assembly of gold nanoparticles into pristine double-helical superstructures (Figure 
1.7). Since this work, the Rosi group has continued to develop their methodology with emphasis 
on: 1) exploring the construction of new nanoparticle assembly architectures, 2) controlling the 
structure metrics of nanoparticle assemblies, and 3) studying their structure-dependent 
properties.  
 
 
Figure 1.7. Left-handed gold nanoparticle double helices are synthesized and assembled directly in a reaction 
containing HEPES buffer solutions of chloroauric acid and C12-PEPAu. TEM image and electron tomography data of 
the double-helical gold nanoparticle superstructure are shown. (Adapted from ref. 25) 
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 The central component of the peptide-based nanoparticle assembly methodology is the 
peptide conjugate (Figure 1.8). As mentioned above, the peptide conjugate plays a dual role in 
that it functions both as the molecular self-assembling building block and as a nanoparticle 
binding agent. Therefore, in order to target new assembly architectures and control their structure 
metrics (emphasis 1 and 2), new peptide conjugate molecules must be employed. To address this, 
several past and ongoing studies have focused on modifying the peptide conjugate. These 
modifications include: varying the R-group,62 incorporating additional residues to the N- and C-
termini,65 controlling amino acid chirality,61 varying the peptide valency,62 modifying the 
chemical oxidation state of residues,63 and utilizing different peptide sequences to bind particles 
of different compositions (Figure 1.8).11 
 
 
Figure 1.8. The peptide conjugate and the various modifications for tuning its assembly. 
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1.3.3 Chiroptical properties of helical nanoparticle superstructures 
In addition to assembling nanoparticle superstructures, the Rosi group has also investigated the 
properties and applications of these hybrid structures (emphasis 3). As mentioned in Section 
1.2.1, the optical properties of metal nanoparticles are dependent not only on their size, shape, 
and composition, but also on their spatial arrangement with respect to one another. This was 
clearly evidenced by the interesting chiroptical properties of the aforementioned double-helical 
gold nanoparticle superstructures (Figure 1.9). Song et. al. showed that gold nanoparticles 
arranged into a chiral superstructure give rise to a circular dichroism response at the plasmonic 
wavelength of the nanoparticle assembly.61 This chiroptical property has sparked interest because 
of their potential applications as chiroptical sensors,66-68 circular polarizers,69-70 and 
metamaterials.17, 69-70   
 
 
Figure 1.9. Circular dichroism spectra for left- and right-handed gold nanoparticle double helices (blue and red line, 
respectively) and the 3D surface rendering of the tomographic volumes revealing the left- and right-handed nature of 
the double helices are shown. (Adapted from ref. 61) 
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1.4 OBJECTIVES AND OUTLINES 
Before I joined the lab in 2012, much of the research conducted in the group centered around 
exploring new nanoparticle superstructures through manipulation of the peptide conjugate 
building block as described in Section 1.3.2. This work provided a foundation for my dissertation 
studies aimed at i) rationally controlling and tuning nanoparticle assembly architectures, ii) 
systematically modifying the surface chemistry of nanoparticle superstructures, and iii) 
developing a more complete understanding of the peptide assembly scaffold underlying the 
nanoparticle superstructure. In addition, prior peptide conjugates explored in the Rosi group 
incorporated only simple R-groups (aliphatic carbons or biphenyl molecules). While these 
proved useful in assembling many interesting and previously unobserved nanoparticle 
superstructures, these moieties are limited as they carry no encoded information that could be 
used, for example, to build responsive or dynamic assemblies. As a last aim, I explored the 
assembly of peptide conjugates having functional, responsive R-groups. 
 Throughout my PhD work, I specifically addressed these areas of opportunity. In Chapter 
2, I describe the use of multivalent peptide conjugates to control the structure metrics of double-
helical gold nanoparticle superstructures, such as their pitch (Langmuir 2015, 31, 9492-9501). In 
Chapter 3, I describe the construction of chiral single-helical nanoparticle superstructures that 
exhibit intense chiroptical activity, and I develop a comprehensive peptide assembly model that 
accounts for their assembly (J. Am. Chem. Soc. 2016, 138, 13655-13663). Chapter 4 describes 
new methods for tuning the structures of hollow spherical gold nanoparticle superstructures 
including nanoparticle coverage density and sphere diameters. I also determine routes to stabilize 
their assembly and tune their surface chemistry (manuscript in preparation). Finally, in Chapter 
5, I describe a new research direction that involves the design, synthesis, and assembly of 
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peptide-oligonucleotide chimeras (POCs) (manuscript submitted). I develop design rules that 
govern their assembly and show that one can logically alter and predict their morphology.  
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2.0  ADJUSTING THE METRICS OF 1D HELICAL GOLD NANOPARTICLE 
SUPERSTRUCTURES USING MULTIVALENT PEPTIDE CONJUGATES 
This work, written in collaboration with Joseph Slocik, Martin G. Blaber, George C. Schatz, 
Rajesh Naik, and Nathaniel L. Rosi*, is reprinted with permission from Langmuir 2015, 31, 
9492-9501. Copyright 2015, American Chemical Society. The supporting information is found in 
Appendix A. 
Dr. Joseph Slocik performed the QCM binding studies. Dr. Martin G. Blaber conducted 
the computational modeling studies of the effect of pitch on CD intensity. 
2.1 INTRODUCTION 
As mentioned in Chapter 1, nanoparticle superstructures exhibit collective properties that are 
dependent on their morphology and structure.71-75 Therefore, methods that allow one to tune and 
optimize these collective properties are important for proposed applications. There are numerous 
studies that explore soft assembly structure as a function of peptide sequence and peptide 
terminus modification;48, 76-78 however, few accounts exploit these highly tunable nanoscale soft 
assemblies as a means for designing programmable, precisely ordered nanoparticle 
superstructures.58, 61, 65  
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Previously, we used a peptide conjugate, C12-PEPAu to direct the assembly of chiral gold 
nanoparticle double helices.25 These assemblies exhibit a collective plasmonic circular dichroism 
(CD) signal arising from the chiral arrangement of discrete achiral nanoparticles.61 Chiral 
nanoparticles and chiral nanoparticle assemblies are receiving significant interest, and tuning 
their chiroptical properties is important for potential applications.17, 66-68 However, adjusting the 
structure of helical nanoparticle assemblies has not been extensively explored experimentally. 
Govorov and co-workers computationally investigated the chiroptical signal of “ideal” 
nanoparticle helices as a function of defects and helical structure parameters.79 They showed that 
adjusting the pitch and other metrics of the helix modulates the strength of the CD signal. 
Moreover, computational modeling of the CD behavior of double-helical gold nanoparticle 
superstructures prepared by our group indicates that the CD signal strength is dependent on 
structural parameters including helix pitch (Figure S2.37) and nanoparticle size.61 Motivated by 
these computational studies that illustrate the need for fine-tuning helical nanoparticle 
superstructures, we aimed to use peptides to systematically control the structural parameters of 
double-helical gold nanoparticle assemblies via simple synthetic modifications to the peptide 
conjugate. Specifically, we address two important design factors of acylated peptide conjugates 
on their peptide assembly: (i) the length of the aliphatic tail and (ii) the steric requirements of the 
peptide. We present a study that explores the effect of these two factors on various structural 
metrics of assembled fibers and helical gold nanoparticle superstructures. 
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2.2 RESULTS AND DISCUSSION 
In previous research, C12-PEPAu conjugates assemble into 1D twisted fibers.25 From structure and 
spectroscopy studies, it was determined that the handedness of the fibers derives from the 
chirality of the peptides,61 which pack laterally perpendicular to the fiber axis. A reported 
assembly model that is consistent with these observations is illustrated in Figure 2.10.76 In this 
model, the peptide conjugates associate in an end-to-end fashion through hydrophobic 
interactions between aliphatic tails and amino acid side chain interactions between the peptide 
head groups to form layers with a certain width (w) that span the width of the fiber. Of course, 
this ignores restructuring that likely occurs because the structural model allows for direct 
exposure of the aliphatic tails to water. The fiber thickness, d, is determined by the length of the 
peptide bilayer and should remain relatively constant. 
 
 
Figure 2.10. (a) Peptide conjugate consisting of a peptide headgroup and an aliphatic chain; (b) peptide conjugates 
associate in an end-to-end fashion via hydrophobic interactions between aliphatic tails and amino acid side chain 
interactions between peptide headgroups; (c) assembly scheme illustrating the assembly of twisted fibers from 
peptide conjugate building blocks (fiber width, w, and fiber thickness, d, are indicated). 
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 With this model as the assembly basis, we designed a series of peptide conjugates in 
which we varied the number of peptide head groups to systematically control the sterics of the 
peptide portion. Within this series, we also adjusted the length of the aliphatic tail. In total, we 
prepared a new family of 12 peptide conjugate molecules containing either 1, 2, or 3 peptide 
head groups and having either 12-, 14-, 16-, or 18-carbon aliphatic chains attached to their N-
termini: monovalent conjugates C12-(PEPAu)1, C14-(PEPAu)1, C16-(PEPAu)1, C18-(PEPAu)1; divalent 
conjugates C12-(PEPAu)2, C14-(PEPAu)2, C16-(PEPAu)2, C18-(PEPAu)2; and trivalent conjugates C12-
(PEPAu)3, C14-(PEPAu)3, C16-(PEPAu)3, C18-(PEPAu)3 (Table 1.1). We used Cu(I)-catalyzed azide-
alkyne cycloaddition “click” chemistry to efficiently synthesize the conjugates.80-81 The 
conjugates were prepared by reacting N-terminal azido-modified PEPAu (N3-PEPAu = N3-
C4H8CO-AYSSGAPPMPPF, Figure S2.38) with aliphatic tails (C12, C14, C16, or C18) 
functionalized with 1, 2, or 3 alkyne groups (Figure S2.39). The identity of the alkyne substrates 
was confirmed using 1H NMR spectroscopy. The peptide conjugates were purified using reverse-
phase high-performance liquid chromatography (HPLC), and their composition was confirmed 
using mass spectrometry (Figure S2.40, Figure S2.41). 
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Table 1.1. Family of 12 peptide conjugate molecules with varying number of peptide head groups and varying 
aliphatic tail lengths 
 
 
2.2.1 Soft assembly of peptide conjugates 
Soft assembly studies were performed to determine how the conjugates assemble in aqueous 
buffer. Each conjugate was dissolved in a mixture of HEPES buffer (pH 7.3) and citrate. These 
conditions were chosen because they are used for the nanoparticle synthesis and assembly 
experiments (vide infra). The –COOH at the C-termini of the peptides are deprotonated at pH 
7.3, so CaCl2 was added to the solutions to provide Ca2+ ions that could shield the negatively 
charged carboxylates and promote assembly of the conjugates.82 After each solution was allowed 
to sit at room temperature for 1 day, TEM was used to observe and characterize the soft 
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assemblies (Figure 2.11). Depending on the conjugate, either 1D fibers or small 
spheres/aggregate structures were observed. Fibers were the predominant product for all the 
monovalent and divalent conjugates, except for C12-(PEPAu)2, for which no clear assembled 
structures were observed. Twisted ribbon fiber morphologies were clearly observed for the 
monovalent conjugates. In addition, some spherical structures were observed for C12-(PEPAu)1 
and C14-(PEPAu)2. Generally, more fibers were observed under TEM as the length of the aliphatic 
tail increases. Only small spherical assemblies/aggregate structures were observed for the 
trivalent conjugates. We concluded from these assembly studies that the propensity for a 
conjugate to assemble into fibers is dictated by the relative ratio of its hydrophobic (aliphatic 
tail) and hydrophilic (peptide) components. As the length of the hydrophobic tail increases, the 
likelihood of forming fibers increases. If the aliphatic tail is too short relative to the size of the 
peptide head group, the conjugates do not assemble into fibers. In these cases, to maximize the 
interactions between the hydrophobic tails, the peptide conjugates assemble into 
spherical/aggregate structures. The relative solubilities of the conjugates are also important. The 
peptide head group is relatively soluble due to numerous hydrogen bonding sites along the 
peptide; therefore, increasing the peptide valency would decrease the overall hydrophobicity of 
the conjugate and lower the driving force for assembly. 
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Figure 2.11. Negatively stained TEM images of the peptide conjugate soft assemblies as a function of peptide 
valency and aliphatic chain length (scale bar = 100 nm): (a) C12-(PEPAu)1, (b) C14-(PEPAu)1, (c) C16-(PEPAu)1, (d) 
C18-(PEPAu)1, (e) C12-(PEPAu)2, (f) C14-(PEPAu)2, (g) C16-(PEPAu)2, (h) C18-(PEPAu)2, (i) C12-(PEPAu)3, (j) C14-
(PEPAu)3, (k) C16-(PEPAu)3, and (l) C18-(PEPAu)3. 
 
 Having established that the monovalent and divalent conjugates assemble into fibers, we 
next examined how valency and aliphatic tail length affect fiber width, thickness, and pitch. 
Fiber widths were measured from the TEM images (Figure 2.12). Fibers assembled from 
divalent conjugates had narrower widths than those assembled from monovalent conjugates, and 
in both cases the aliphatic tail length does not significantly affect the fiber width. This 
observation is consistent with the reported model (Figure 2.10). The fiber width correlates with 
the extent of lateral packing, and the monovalent conjugates can presumably assemble more 
easily laterally (Figure 2.13a) compared to the divalent conjugates (Figure 2.13b) because their 
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peptide head group has a smaller steric requirement. This allows for more favorable side-by-side 
packing for the monovalent conjugates and greater hydrophobic interactions between the 
aliphatic tails compared to the divalent conjugates. Peptide conjugate packing within the 
assemblies was studied using attenuated total reflectance Fourier-transform infrared (ATR-FTIR) 
spectroscopy. IR spectroscopy can provide information about the internal structure of the 
fibers.83 Briefly, C18-(PEPAu)1, C18-(PEPAu)2, and C18-(PEPAu)3 were dissolved in a 1:1 mixture of 
CH3CN and Nanopure water (NP H2O), and the solution was directly drop-cast onto the ATR-
FTIR substrate. The solution was allowed to slowly evaporate to induce assembly. Both C18-
(PEPAu)1 and C18-(PEPAu)2 formed fibers, while C18-(PEPAu)3 formed spherical structures (Figure 
S2.42). The signals observed at 2920, 2924, and 2925 cm-1 for C18-(PEPAu)1, C18-(PEPAu)2, C18-
(PEPAu)3, respectively, correspond to C-H vibrations (Figure 2.13d). The signal for C18-(PEPAu)1 
 
 
Figure 2.12. Nanofiber width distribution for (a) C12-(PEPAu)1, 12.6 ± 1.3 nm based on 60 counts; (b) C14-(PEPAu)1, 
12.1 ± 1.7 nm based on 70 counts; (c) C16-(PEPAu)1, 12.6 ± 1.1 nm based on 100 counts; (d) C18-(PEPAu)1, 13.8 ± 1.1 
nm based on 100 counts; (e) C14-(PEPAu)2, 8.9 ± 0.9 nm based on 70 counts; (f) C16-(PEPAu)2, 9.3 ± 1.2 nm based on 
100 counts; and (g) C18-(PEPAu)2, 8.3 ± 0.9 nm based on 100 counts. 
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is the same for what is observed for crystalline polymethylene chains (ν ~2920 cm-1), and the 
signals for C18-(PEPAu)2 and C18-(PEPAu)3 are closer to what is observed for the liquid state (v 
~2928 cm-1).84-85 These data suggest a greater amount of disorder within the aliphatic core of the 
divalent and trivalent peptide conjugate assemblies in comparison to the monovalent peptide 
conjugate assemblies, which is consistent with the assembly model and our fiber width 
measurements. Specifically, we expect greater order in the monovalent conjugate assemblies 
because the conjugates can more effectively pack together (Figure 2.13a) than the divalent 
(Figure 2.13b) or trivalent conjugates (Figure 2.13c). This efficient packing leads to better 
lateral assembly and larger fiber widths. 
 
 
Figure 2.13. Packing model of (a) C18-(PEPAu)1, (b) C18-(PEPAu)2, and C18-(PEPAu)3 assemblies. (d) C-H vibration 
bands in the IR spectra of C18-(PEPAu)1 (blue line), C18-(PEPAu)2 (red line), and C18-(PEPAu)3 (green line) assemblies. 
 
From the TEM images the monovalent conjugates clearly assemble into twisted fibers. In 
these cases, the fiber thickness (d in Figure 2.10) could be measured at the twist point where the 
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width of the fiber is aligned perpendicular to the surface of the TEM grid (Figure 2.14a). The 
fiber thicknesses were ~9 nm and remained relatively consistent between assemblies, regardless 
of aliphatic tail length (Figure 2.14b-e). However, because the AFM data indicate that the 
divalent fibers are twisted (vide infra), we speculate that the thickness (d) and the width (w) are 
nearly the same (~9 nm). 
 
 
Figure 2.14. (a) TEM image showing the twist points used to measure the fiber thickness (scale bar = 100 nm). 
Fiber thickness distribution of (b) C12-(PEPAu)1: 8.7 ± 1.0 based on 30 counts; (c) C14-(PEPAu)1: 8.9 ± 1.2 based on 
60 counts; (d) C16-(PEPAu)1: 8.8 ± 0.9 based on 60 counts; (e) C18-(PEPAu)1: 10.3 ± 1.9 based on 30 counts. 
 
TEM and AFM were used to study the fiber helicity (Figure S2.43-S2.50). From AFM, 
helical segments of the fibers were analyzed to determine their pitch. The fibers assembled from 
C12-(PEPAu)1, C14-(PEPAu)1, C16-(PEPAu)1, and C18-(PEPAu)1 had average pitch values of 186 ± 13 
nm, 196 ± 11 nm, 214 ± 7 nm, and 238 ± 30 nm, respectively (Figure S2.44-S2.47). Because 
these twisted fibers were sufficiently wide, TEM could also be used to measure their pitch 
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(Figure S2.43). For the divalent conjugates, C16-(PEPAu)2 and C18-(PEPAu)2, the average pitch 
measured from AFM was 178 ± 20 nm and 184 ± 15 nm, respectively (Figure S2.49 and Figure 
S2.50).  We were not able to observe fibers for C14-(PEPAu)2 (Figure S2.48); instead, spherical 
structures were observed.  We attribute this to the low yield of fibers formed for this conjugate 
compared to C16-(PEPAu)2 and C18-(PEPAu)2, based on the TEM data.  From these data, it was 
determined that the pitch i) increases with increasing aliphatic chain length; and ii) decreases 
with increasing peptide valency. These results are consistent with previous reports where larger 
fiber width leads to twisted fibers having longer pitch.40, 76 To summarize, monovalent 
conjugates, which have larger fiber widths (more lateral packing) are less prone to twisting than 
their divalent counterparts, which have narrower widths.   
2.2.2 Nanoparticle assembly studies 
After studying the soft assembly behavior of the fibers, we proceeded to prepare nanoparticle 
assemblies using the peptide conjugates. The peptide conjugates were dissolved in a mixture of 
HEPES buffer and citrate. HEPES functions as the primary reducing agent for the gold ions and 
assists in dissolving the peptide conjugates.55, 86 An aliquot of a solution of HAuCl4 in 1.0 M 
TEAA buffer was added and the resulting solution was vortexed and then left undisturbed at 
room temperature for several hours. Nanoparticle assemblies were observed by TEM (Figure 
2.15). The morphology of the nanoparticle assemblies formed from the different peptide 
conjugates corresponds to the morphology of the respective soft assembly structures. 1D 
nanoparticle assemblies were observed for the conjugates that assembled into 1D fibers; 
randomly distributed nanoparticles were observed for the conjugates that did not assemble into 
fibers. In previous work, we found that conjugates that assemble rapidly into fibers tend to yield 
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poorly-formed nanoparticle superstructures with irregular particle shapes and diameters.58 On the 
other hand, conjugates that assemble more slowly tend to yield more well-defined 
superstructures with clear morphological features and regular particle diameters.25 In cases where 
conjugates assemble very slowly, either no nanoparticle assemblies or rather ill-formed 
assemblies are observed. A preponderance of evidence, both published and unpublished, 
suggests that the peptide conjugates must first associate with small gold particles prior to 
assembly in order to form a well-defined superstructure.58 Thus, there exists a delicate balance 
between particle growth, particle-peptide conjugate binding, and peptide conjugate assembly that 
must be realized to produce well-defined nanoparticle superstructures. In this study, the 
conjugate that assembles most rapidly into fibers, C18-(PEPAu)1, and the one that assembles most 
slowly into fibers, C12-(PEPAu)1, form poorly defined linear superstructures with many 
overlapping nanoparticles. Conjugates having intermediate assembly rates (e.g., C14-(PEPAu)1, 
C16-(PEPAu)1, C16-(PEPAu)2, and C18-(PEPAu)2) tend to form more well-defined nanoparticle 
superstructures consisting of co-linear chains of nanoparticles; in each of these cases, the 
nanoparticle superstructures exhibit regions of helicity (vide infra). 
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Figure 2.15. TEM images of the nanoparticle assemblies as a function of peptide valency and aliphatic chain length 
(scale bar = 100 nm): (a) C12-(PEPAu)1, (b) C14-(PEPAu)1, (c) C16-(PEPAu)1, (d) C18-(PEPAu)1, (e) C12-(PEPAu)2, (f) 
C14-(PEPAu)2, (g) C16-(PEPAu)2, (h) C18-(PEPAu)2, (i) C12-(PEPAu)3, (j) C14-(PEPAu)3, (k) C16-(PEPAu)3, and (l) C18-
(PEPAu)3. 
 
 Several structural parameters of the nanoparticle superstructures could potentially affect 
their properties.87-88 We first considered nanoparticle size within the assembled superstructures. 
Nanoparticle diameters were measured from the TEM images (Figure 2.16). The data indicate 
that nanoparticle diameter within the 1D nanoparticle assemblies is dependent on both the 
aliphatic tail length and the valency of the peptide conjugate. Nanoparticle diameter increases 
with increasing aliphatic chain length and decreases with increasing valency. These observations 
led us to hypothesize that the decrease in particle size with increased valency may be due to 
increased binding affinity associated with multivalency.89-91 An increased binding affinity could 
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limit the growth of the nanoparticles. To test this hypothesis, we measured the equilibrium 
binding constants for mono- and divalent peptide conjugates using data from a quartz crystal 
microbalance (QCM) analysis (Figure 2.17). For this experiment, it was important to use mono- 
and divalent conjugates without aliphatic tails in order to prevent assembly before binding to the 
substrate (Figure S2.51). The equilibrium binding constant, Keq, (Keq = Ka/Kd, where Ka is the 
association constant and Kd is the dissociation constant) of the monovalent conjugate was 
slightly higher than that of the divalent conjugate, although the values were very similar. By 
comparison, these are consistent to the binding constants of multivalent dendrons with metal 
oxides and repeating gold-binding peptides.92-93 One possible explanation for the statistically 
similar Keq values is that the proximity of the two peptides in the divalent conjugate prevents 
favorable peptide interaction with the substrate. It is known that AYSSGAPPMPPF adopts a 
specific conformation for optimal binding; a second peptide in close proximity may hinder this 
conformation.89, 94 
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Figure 2.16. Nanoparticle diameters measured from TEM images: (a) C12-(PEPAu)1: 5.3 ± 0.9 nm based on 100 
counts; (b) C14-(PEPAu)1: 6.6 ± 1.2 nm based on 100 counts; (c) C16-(PEPAu)1: 7.6 ± 1.5 nm based on 100 counts; (d) 
C18-(PEPAu)1: 10.2 ± 2.9 nm based on 50 counts; (e) C12-(PEPAu)2: 2.9 ± 0.6 nm based on 100 counts; (f) C14-
(PEPAu)2: 4.5 ± 1.1 nm based on 100 counts; (g) C16-(PEPAu)2: 5.9 ± 1.1 nm based on 100 counts; (h) C18-(PEPAu)2: 
6.1 ± 1.4 nm based on 100 counts; (i) C12-(PEPAu)3: 2.8 ± 0.6 nm based on 50 counts; (j) C14-(PEPAu)3: 2.6 ± 0.5 nm 
based on 100 counts; (k) C16-(PEPAu)3: 3.0 ± 0.6 nm based on 50 counts; (a) C18-(PEPAu)3: 2.8 ± 0.7 nm based on 
100 counts. 
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Figure 2.17. QCM binding data for the (a) monovalent and (b) divalent peptide conjugates. (c) The association 
binding constant, Ka, dissociation binding constant, Kd, and equilibrium binding constant, Keq, were calculated from 
the QCM experiments. 
 
The variation in particle diameter within the nanoparticle superstructures, however, may 
be explained by the interplay between fiber formation and nanoparticle binding (vide supra).  For 
the conjugates that assemble into fibers, the nanoparticle diameter increases as the propensity to 
form fibers increases, as illustrated in going from C12-(PEPAu)1 to C18-(PEPAu)1 (Figure 2.16a-d) 
and in going from C14-(PEPAu)2 to C18-(PEPAu)2 (Figure 2.16f-h). If the peptide conjugate 
monomers rapidly assemble into fibers, they have less time free in solution to cap the growth of 
the growing nanoparticles. This leads to larger particle diameters. Conversely, if the peptide 
conjugate monomers slowly assembly into fibers, they will have more time free in solution to 
cap the growth of the nanoparticles, leading to smaller nanoparticle diameters. When 
nanoparticle assembly was not observed (C12-(PEPAu)2, C12-(PEPAu)3, C14-(PEPAu)3, C16-
(PEPAu)3, and C18-(PEPAu)3), the particles are uniformly small (~3 nm), independent of valency 
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and tail length (Figure 2.16e,i-l). In these cases, the peptide conjugates remain in solution and 
have adequate time to bind to the growing nanoparticles to cap their growth. 
We next considered structural metrics of the linear nanoparticle superstructures, 
including the distance between the co-linear nanoparticle chains as well as the helical pitch. The 
interchain distances of the nanoparticle superstructures constructed using C14-(PEPAu)1, C16-
(PEPAu)1, C16-(PEPAu)2, and C18-(PEPAu)2 were measured via TEM (Figure S2.52). These 
conjugates were chosen because they yielded the most well-defined superstructures in which two 
co-linear chains can clearly be identified. The interchain distances for the C14-(PEPAu)1 and C16-
(PEPAu)1 superstructures were 5.9 ± 1.2 nm and 5.6 ± 1.2 nm, respectively, while those for the 
C16-(PEPAu)2 and C18-(PEPAu)2 superstructures were 4.6 ± 1.2 and 5.0 ± 1.4 nm, respectively. 
Although we cannot determine whether the particles are bound to the edge or the face of the 
fibers (Figure S2.53), the similar interchain distances suggests that the particles are bound to the 
fiber faces, because the fiber thicknesses are approximately the same, whereas the fiber widths 
for the monovalent and divalent are different. 
Nanoparticle superstructures formed using C14-(PEPAu)1, C16-(PEPAu)1, C16-(PEPAu)2, and 
C18-(PEPAu)2 each exhibit regions of helicity (Figure 2.18 and Figure S2.54). The helicity is 
most clearly defined in the C16-(PEPAu)1- and C18-(PEPAu)2-based nanoparticle superstructures 
(Figure 2.18). The average pitch for C16-(PEPAu)1 and C18-(PEPAu)2, ~204 and ~173 nm, 
respectively, are similar to the average pitch values of the C16-(PEPAu)1 and C18-(PEPAu)2 
nanofibers as determined by AFM (214 ± 7 and 184 ± 15 nm, respectively). These measurements 
suggest that the peptide conjugate assembly directs the structure of the nanoparticle assembly. 
Moreover, these results, when taken together with our reported results on C12-PEPAu double-
helical gold nanoparticle superstructures (pitch ~85 nm),25 indicate that modifications to the 
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peptide conjugate can allow one to adjust the pitch of double-helical nanoparticle 
superstructures.  
 
 
Figure 2.18. TEM images of nanoparticle assemblies showing regions of helicity and pitch measurements from (a) 
C16-(PEPAu)1 and (b) C18-(PEPAu)2 (scale bar = 100 nm). 
2.3 CONCLUSION 
We have prepared a family of peptide conjugate molecules in which the aliphatic tail length and 
peptide valency were systematically varied. The conjugates have an increased propensity to form 
twisted 1D fibers as the tail length increases and the valency decreases. In cases where twisted 
1D fibers formed, we found that the pitch of the fibers was inversely proportional to valency and 
proportional to tail length while the width of the fibers decreased with increasing valency. The 
peptide conjugates were used to direct the assembly of nanoparticle superstructures, whose 
morphology and structural parameters correspond to those of the soft assemblies. The metrics of 
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the nanoparticle superstructures, including interchain distance and helical pitch correspond 
closely to the metrics of the conjugate soft assemblies. These results illustrate the ability to 
control and tailor the metrics of 1D helical nanoparticle superstructures through synthesis and 
assembly of peptide conjugate molecules, and they represent an important step forward in our 
ability to prepare programmable nanoparticle superstructures by design. 
2.4 EXPERIMENTAL SECTION 
2.4.1 General methods and instrumentations 
All chemicals were purchased from either Aldrich or Fisher and used without further 
purification. N3-C4H8CO-AYSSGAPPMPPF (N3-PEPAu, Figure S2.38) was synthesized by the 
University of Pittsburgh Peptide Synthesis Facility or New England Peptide. Triethylammonium 
acetate buffer (TEAA) was purchased from Aldrich (catalog number: 90358) and 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (pH = 7.3) (HEPES) buffer was purchased from 
Fisher (catalog number: BP299-100). Chloroauric acid (HAuCl4) was purchased from Aldrich 
(catalog number: 520918). 0.1 M citrate (pH 7.4) was prepared by dissolving citric acid in 
Nanopure water and adjusting the pH to 7.4 using NaOH. Peptide conjugates were purified using 
an Agilent 1200 Series reverse-phase high-pressure liquid chromatography (HPLC) instrument 
equipped with an Agilent Zorbax 300SB-C18 column. Peptide conjugates were quantified based 
on their absorbance at 280 nm and using the extinction coefficient for tyrosine (1280 M-1cm-1). 
Spectra were collected using an Agilent 8453 UV-Vis spectrometer equipped with deuterium and 
tungsten lamps. Transmission electron microscopy (TEM) samples were prepared by drop-
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casting 6 µL of solution onto a 3-mm-diameter copper grid. TEM images were collected with a 
FEI Morgagni 268 (80 kV) equipped with an AMT side mount CCD camera system. 
Phosphotungstic acid (pH 7.4) was used to stain TEM sample grids for soft assembly studies. All 
proton nuclear magnetic resonance (1H NMR) data were collected using a Bruker Avance III 300 
MHz spectrometer. All liquid chromatography mass spectrometry (LC-MS) data were collected 
using a Shimadzu LC-MS 2020. Matrix assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) data were collected using an Applied Biosystem Voyager 
System 6174 MALDI-TOF mass spectrometer (positive reflector mode; accelerating voltage: 
20kV) and using α-cyano-4-hydroxycinnamic acid (CHCA) as the ionization matrix. Atomic 
force microscopy (AFM) samples were prepared on freshly cleaved mica (sample incubated for 5 
min. and washed twice with Nanopure water) and analyzed in tapping-mode using an Asylum 
MFP-3D atomic force microscope. Attenuated total reflectance Fourier-transform infrared (ATR-
FTIR) spectra were collected on a Perkin Elmer Spectrum 100 FTIR with a universal attenuated 
total reflectance sampling accessory coupled to a computer using Perkin Elmer Spectrum 
Express software; the peptide conjugates were dissolved in a solution of acetonitrile/Nanopure 
water (1:1) and drop-casted onto the sample stage. A Q-Sense E4 quartz crystal microbalance 
with dissipation (QCM-D) was used to measure peptide conjugate binding on gold. Gold-coated 
QCM sensors (Q-Sense) were cleaned via UV-ozone treatment for 10 minutes, followed by 
heating in a 7.5:1:1 solution of double deionized water/30% H2O2/NH4OH at 80°C for 10 
minutes. The sensors were thoroughly rinsed with double deionized water, and dried with N2. 
The clean gold-coated sensors were mounted in a Q-Sense window flow cell module. For peptide 
conjugate binding, a flow rate of 0.17 mL/min. was used at a constant temperature of 23°C, and 
the 3rd overtone resonance was monitored. Nanopure water (NP H2O, 18.2 MΩ) was obtained 
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from a Barnstead DiamondTM water purification system. All TEM and AFM measurements were 
made using ImageJ software. 
2.4.2 Preparation of peptide conjugates 
Alkyne-terminated aliphatic substrates were prepared according to protocols detailed in 
Appendix A. The peptide conjugates were prepared using copper(I)-catalyzed azide-alkyne 
cycloaddition (CuAAC) in which N3-PEPAu was reacted with particular alkyne-terminated 
aliphatic substrates. A representative protocol for the preparation of C16-(PEPAu)2 is detailed 
here. The following stock solutions were prepared: A, 24.7 mM divalent alkyne in 
tetrahydrofuran (THF); B, 198.3 mM CuSO4 in NP H2O; C, 37.3 mM tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA) in NP H2O; and D, 101.0 mM sodium ascorbate 
in NP H2O. In a 2 mL glass vial, N3-PEPAu (3 mg, 2.23 μmol) was dissolved in 462.3 µL of THF 
and 337.5 µL of NP H2O. To this vial were added 37.7 µL A, a mixture of B and C (14.1 µL B 
mixed with 74.8 µL C), and 73.6 µL D. The vial was capped, wrapped in aluminum foil, and 
stirred for at least 4 hrs. at room temperature. Dimethylformamide (100 µL) was added to the 
product solution. The resulting solution was passed through a 0.2 µm syringe filter (Whatman, 
catalog number 6789-1302). The reaction vial was washed with 400 µL of a 1:1 mixture of NP 
H2O and acetonitrile (CH3CN), and this wash was passed through the same 0.2 µm syringe filter 
and mixed with the DMF/product solution. This final solution containing the product peptide 
conjugate was purified using reverse-phase HPLC eluting with a linear gradient of 0.05% formic 
acid in CH3CN and 0.1% formic acid in NP H2O (5/95 to 95/5 over 30 min.). 
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2.4.3 Preparation of soft assemblies 
In a plastic vial, lyophilized peptide conjugates (~3.75 x 10-8 mol) were dissolved in 250 µL of a 
1:4 mixture of 0.1 M citrate and 0.1 M HEPES buffer. 2 µL of a 0.1 M CaCl2 solution in NP H2O 
was added to the peptide conjugate solution. The resulting solution was vortexed briefly and then 
allowed to sit undisturbed at room temperature. TEM and/or AFM samples were prepared after 1 
day of incubation at room temperature. 
2.4.4 Preparation of nanoparticle assemblies 
In a plastic vial, lyophilized peptide conjugates (~1.87 x 10-8 mol to ~7.49 x 10-8 mol) were 
completely dissolved in 250 µL of a 1:4 mixture of 0.1 M citrate and 0.1 M HEPES buffer and 
allowed to sit at room temperature for 30 min. A fresh stock solution of HAuCl4 in TEAA buffer 
was prepared by mixing 100 µL of 0.1 M HAuCl4 in NP H2O with 100 µL of 1.0 M TEAA 
buffer. The resulting mixture was vortexed for 1 minute. After sitting 30 min. at room 
temperature, 2 µL of the freshly prepared HAuCl4/TEAA solution was added to the peptide 
conjugate solution. A dark precipitate appeared 2-4 seconds after the addition of the 
HAuCl4/TEAA solution; at this time, the vial was briefly vortexed and then left undisturbed at 
room temperature. TEM samples were prepared after 4 hrs. of incubation at room temperature. 
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3.0  PEPTIDE-DIRECTED ASSEMBLY OF SINGLE-HELICAL GOLD 
NANOPARTICLE SUPERSTRUCTURES EXHIBITING INTENSE CHIROPTICAL 
ACTIVITY 
This work, written in collaboration with Jennifer C. Boatz, Abhishek Mandal, Gongpu Zhao, 
Soumitra Mokashi Punekar, Chong Liu, Xianting Wang, Peijun Zhang, Patrick C. A. van der 
Wel*, and Nathaniel L. Rosi*, is reprinted with permission from the Journal of the American 
Chemical Society 2016, 138, 13655-13663. Copyright 2016, American Chemical Society. The 
supporting information is found in Appendix B. 
Jennifer C. Boatz and Abhishek Mandal conducted and processed the MAS solid-state 
spectroscopy experiments. Dr. Gongpu Zhao and Xianting Wang performed and analyzed the 
cryo-electron tomography data. Soumitra Mokashi Punekar assisted with synthesizing the single 
helices. Dr. Chong Liu collected the powder XRD data. 
3.1 INTRODUCTION 
As described in Chapter 1, chiral nanoparticle assemblies are an emerging class of materials, 
which have the potential to serve as nanoscale circular polarizers69-70 and chiroptical sensors,66-68 
and they represent an interesting new entry into the metamaterials catalogue.17, 69-70 Peptides, 
which can assemble into chiral architectures, are attractive molecular building blocks that can be 
 39 
used to direct the assembly of nanoparticles into chiral superstructures. Previously our group has 
constructed chiral double-helical gold nanoparticle superstructures and characterized their unique 
chiroptical properties.61 While significant progress has been made toward (i) understanding how 
PEPAu associates with gold nanoparticle surfaces26, 55, 94-97 and (ii) understanding how both R-
groups and intrinsic secondary structure influence R-PEPAu assembly,25, 60, 62 we have yet to 
establish a molecular-level understanding that accounts for the dual role that R-PEPAu conjugates 
play in the context of constructing nanoparticle superstructures. Significant questions remain 
unanswered: How does PEPAu associate to nanoparticles within an assembled nanoparticle 
superstructure? How do R-PEPAu conjugates pack and assemble within a nanoparticle 
superstructure? How do these conjugates simultaneously self-assemble and bind to gold 
nanoparticle surfaces? Uncovering answers to these questions is paramount to advancing 
peptide-based methods for assembling nanoparticle superstructures.  
Here, we report the preparation of unique gold nanoparticle single helices that exhibit 
exceptionally strong plasmonic chiroptical activity. Motivated by these results, we rigorously 
examine the underlying molecular basis of these superstructures and ultimately arrive at a 
structural model that thoroughly accounts for their assembly. Through these studies, we make 
considerable progress toward answering the fundamental questions listed above, and we 
ultimately arrive at a new understanding of this methodology that will motivate future peptide 
design strategies for the rational construction and optimization of chiral nanoparticle 
superstructures.  
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3.2 RESULTS AND DISCUSSION 
3.2.1 Single helix synthesis and chiroptical properties 
I reported in Chapter 2 that the divalent peptide conjugate, C18-(PEPAu)2, directs the assembly of 
double-helical gold nanoparticle superstructures when mixed with gold salts, assembly buffers, 
and reducing agents (Figure 3.19a). In subsequent studies, single-helical gold nanoparticle 
superstructures, rather than double helices, were, at times, observed as the sole product. These 
confounding results prompted us to investigate the origin of the single helix architecture. Since 
the synthetic procedures used to prepare the double and single helices were virtually 
indistinguishable (e.g., identical gold salt, identical buffer, and identical reagent concentrations), 
we carefully characterized the C18-(PEPAu)2 used in each synthesis, reasoning that a small 
impurity or chemical change to the conjugate may have led to the observed results. High 
resolution liquid chromatography mass spectrometry (HR-LCMS) revealed that the molecular 
weight of the conjugates that directed the formation of the single helices was 16 m/z larger than 
expected (z = 2), corresponding to a 32 au increase in the molecular weight. The thioether 
functional group of methionine can undergo oxidation to the sulfoxide; a 16 m/z increase would 
result if both methionine residues of C18-(PEPAu)2 were oxidized (Figure S3.55b). Therefore, we 
hypothesized that oxidation of C18-(PEPAu)2 to C18-(PEPAuM-ox)2 (PEPAuM-ox = 
AYSSGAPPMoxPPF) results in the formation of single-helical superstructures. To test this 
hypothesis, we chemically oxidized C18-(PEPAu)2; LCMS data for these oxidized conjugates 
confirmed the increase in molecular weight associated with the addition of two oxygens (Figure 
S3.56). The oxidized conjugates exclusively directed the assembly of single-helical gold 
nanoparticle superstructures (Figure 3.19b). 
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Figure 3.19. Preparation of (a) double- and (b) single-helical nanoparticle superstructures from C18-(PEPAu)2 and 
C18-(PEPAuM-Ox)2, respectively, under identical reaction conditions. C18-(PEPAuM-Ox)2 was prepared via oxidation 
using H2O2. 
 
We next characterized the single-helical gold nanoparticle assemblies. Transmission 
electron microscopy (TEM) images (Figure 3.20a-c and Figure S3.57) reveal that the single 
helices have an average pitch of 94.4 ± 6.6 nm (Figure 3.20d) and are composed of individual 
rod-like nanoparticles with lengths of 16.6 ± 3.0 nm and widths of 9.6 ± 1.9 nm (Figure S3.58). 
At the early stages of the synthesis and assembly process, the nanoparticles are spherical and 
bound to the 1D C18-(PEPAuM-ox)2-based fibers (Figure 3.20c and Figure S3.59), but over time 
they grow into oblong rod-like nanoparticles (Figure S3.59). Throughout the nanoparticle 
growth process, the nanoparticles remain bound to the fibers (Figure S3.59). These observations 
are consistent with our previously reported studies.25, 58 We note that, in this method, in situ 
nanoparticle growth in the presence of the peptide conjugates is required to achieve ordered 
nanoparticle assemblies. Cryogenic electron tomography (cryo-ET) was employed to determine 
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the 3D architecture of the single helices (Figure 3.20e,f). The reconstructed tomographic volume 
confirms that the helices are left-handed, which can be attributed to L amino acid residues 
comprising the peptides. Structural parameters were also gathered from the 3D reconstruction of 
the helices. The pitch is 102.0 ± 2.5 nm, within error of the measured data from 2D TEM images, 
and the rotation angle per particle is 34.3 ± 4.9 degrees, corresponding to approximately 10-11 
nanoparticles per pitch length (Figure S3.60a,b). The inner diameter of the helical superstructure 
is 10.1 ± 0.6 nm (Figure 3.20f and Figure S3.60c). This distance corresponds to the measured 
width of the fibers (vide infra). 
 
 
Figure 3.20. Single helix characterization. (a,b) TEM images of single-helical gold nanoparticle superstructures 
after 15 h of reaction and (c) negative-stained TEM image after 30 min. of reaction. (d) Pitch of the helices, 
measured from TEM (94.4 ± 6.6 nm; based on 80 counts). The cryo-ET 3D reconstruction of the single helices 
reveals their (e) left-handed helicity and, when viewed along the helix axis, their (f) core diameter where the fiber 
resides. (g) CD spectrum of the single-helical superstructures. 
 
Circular dichroism (CD) spectroscopy was used to characterize the chiroptical activity of 
the single helices. The single helices exhibit a strong bisignate peak centered at approximately 
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600 nm, near the collective plasmonic extinction band for the assemblies (Figure 3.20g). Others 
have reported a visible plasmonic CD peak for peptide-capped gold nanoparticles.98 However, 
gold nanoparticles capped with PEPAuM-ox, showed only a weak CD signal (Figure S3.61). 
Therefore, we can reasonably conclude that the strong plasmonic CD signal for the single helices 
originates from the chiral helical arrangement of gold particles; indeed, the observed signal is 
consistent with previous theoretical predictions.61, 88 It is important to compare the chiroptical 
activity of the single helices to other reported chiral nanoparticle assemblies. The anisotropy 
factor, g, is typically used as a benchmark value for determining the intensity of the chiroptical 
signal. Optimized assemblies (Figure S3.62a,b), for which synthetic conditions were tuned to 
increase particle dimensions, have an absolute g-factor up to ~0.04 (Figure S3.62e), which, to 
our knowledge, is one of the highest reported to date for comparable nanoparticle assemblies.99-
102 
3.2.2 Peptide conjugate assembly studies 
The intense chiroptical activity of single helices prompted us to examine the assembly and 
structure of C18-(PEPAuM-ox)2. Understanding the underlying molecular structure of the fibers and 
how it correlates to the final nanoparticle assembly will allow for rational design of peptide 
conjugate building blocks and precise control over nanoparticle superstructure assembly and 
properties. 
We first studied the morphology of the C18-(PEPAuM-ox)2 fibers in the absence of gold 
nanoparticles. Acylated peptide amphiphiles are known to assemble into two principal helical 
morphologies: twisted ribbons and helical ribbons (Figure 3.21a,b).48, 103-107 Both assemblies are 
defined by a cross-β amyloid-like structure. Twisted ribbons are characterized by their saddle-
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like curvature with a C2 symmetry axis and both ribbon faces equally exposed. Helical ribbons, 
on the other hand, have cylindrical curvature and one face of the ribbon is directed toward the 
interior of the helical coil and the other is directed to the exterior. In both cases, the helicity 
originates from the chirality of the peptide-based molecular building blocks.40 The observed 
single helix architecture suggests that C18-(PEPAuM-ox)2 fibers assemble into helical ribbons, and 
the gold nanoparticles decorate the exterior face of the helical ribbon. Evidence from previous 
studies suggests that the twisted ribbon morphology favors the formation of a double-helical 
nanoparticle superstructure, where the particles associate to either both edges or both faces of the 
ribbon.25, 62 
 
 
Figure 3.21. C18-(PEPAuM-ox)2 fiber morphology studies. Helical peptide amphiphile fibers typically exhibit either (a) 
helical ribbon or (b) twisted ribbon morphology. (c) Negative-stained TEM image of C18-(PEPAuM-ox)2 fibers. (d) 
Fiber widths were 10.2 ± 0.8 nm. (e) AFM reveals the helical ribbon morphology of C18-(PEPAuM-ox)2 fibers with a 
pitch of 96.2 ± 4.8 nm and (f) a ribbon height of approximately 4 nm (height trace measured along the dashed line). 
 
To precisely determine the fiber morphology, samples were analyzed using numerous 
microscopy techniques. TEM verifies the presence of 1D fibers (Figure 3.21c), in addition to 
small pseudospherical aggregates, which are always present in varying amounts, depending on 
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the length of time allowed for the assembly process. The fiber widths, measured via TEM, are 
10.2 ± 0.8 nm, which is consistent with the cryo-ET data that defined the inner diameter of the 
nanoparticle superstructure to be approximately 10.1 nm (vide supra) (Figure 3.21d). Distinct 
morphological features of the fibers, such as their helicity, were indistinguishable using 
traditional TEM imaging. Tapping-mode atomic force microscopy (AFM) images clearly reveal 
that the fibers adopt the helical ribbon morphology (Figure 3.21e and Figure S3.63). The pitch, 
measured via AFM, is 96.2 ± 4.8 nm, consistent with the pitch of the gold nanoparticle single 
helices. The vertical thickness of the ribbon is ~4 nm (Figure 3.21f). Height traces along the 
fiber axis suggest that the coiled helical ribbon compresses onto the mica substrate (Figure 
S3.63e), which is not surprising as such compression/collapse is common for soft assemblies 
having a hollow interior.108-109 The morphological similarities between the helical ribbons and 
the gold nanoparticle single helices imply similarities between C18-(PEPAuM-ox)2 assembly in both 
the presence and absence of gold nanoparticles. Consistent with our previous reports, these 
observations suggest that the geometry and structure of the peptide conjugate assembly defines 
the nanoparticle assembly architecture. Studying and understanding the underlying molecular 
structure of the C18-(PEPAuM-ox)2 helical ribbons provides insights into the nature of the 
nanoparticle assembly and provides a basis for future studies aimed at modifying the single-
helical structure. 
We therefore next proceeded to examine the internal structure within the C18-(PEPAuM-ox)2 
fibers. An amide I absorption peak at 1630 cm-1, characteristic of parallel β-sheet secondary 
structure,110-111 was observed in the Fourier transform infrared (FTIR) spectrum (Figure 3.22a). 
In addition, a peak at 2922 cm-1 corresponding to C-H stretches was observed, signifying 
relatively ordered packing of the alkyl chains within the assembly (Figure 3.22a).83 CD spectra 
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for C18-(PEPAuM-ox)2 were collected under conditions that promote fiber assembly.82 A prominent 
negative band centered at ~211 nm and a positive band centered at ~238 nm (Figure 3.22b) were 
observed. Negative peaks corresponding to the presence of β-sheet structure are typically 
observed around 215-220 nm for peptide amphiphile assemblies.76, 112 We speculate that the 
blue-shifted negative peak could be due to the presence of multiple secondary structures within 
the assembly. Molecular simulation studies of PEPAu predict that the proline residues near the C-
terminus adopt a polyproline II (PPII) conformation when free in solution.94  PPII helices 
typically display a strong negative CD band at ~205 nm.113-114 We observe a negative band at 
205 nm for C18-(PEPAuM-ox)2 under conditions that do not promote fiber assembly (i.e. no β-sheet 
formation; Figure S3.64). Therefore, we conclude that the observed signal in the CD spectrum 
of C18-(PEPAuM-ox)2 fibers is a superposition of bands deriving from both β-sheet and PPII 
secondary structure in the assembled fibers. 
 
 
Figure 3.22. Spectroscopy studies. (a) FTIR spectrum of C18-(PEPAuM-ox)2 fibers. Peaks at 1630 cm-1 and 2922 cm-1 
correspond to the amide I band and C-H stretch, respectively. (b) CD spectrum of C18-(PEPAuM-ox)2 in 10 mM 
HEPES and 1 mM CaCl2 after one day, and (c) corresponding negative-stained TEM image of the C18-(PEPAuM-ox)2 
fibers. 
 
While CD and FTIR spectroscopy provided information about the secondary structure, X-
ray diffraction (XRD) experiments were conducted to probe the molecular-level packing of C18-
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(PEPAuM-ox)2 within the fibers. XRD patterns of aligned C18-(PEPAuM-ox)2 fibers displayed the 
prototypical pattern observed for cross-β amyloid-like structure (Figure 3.23a).115-116 An intense 
meridional reflection corresponding to a d-spacing of 4.6 angstroms is attributed to the H-
bonding distances between peptide backbones. Equatorial peaks with d-spacings of ~6.5, ~9, and 
~18 angstroms correspond to repeat distances between β-sheets (Figure 3.23b,c). The off-
meridian reflections corresponding to a d-spacing of ~4.2 may be attributed to the distance 
between hkl planes diagonal to the planes containing the β-sheets.117 
 
 
Figure 3.23. X-ray data. 2D x-ray diffraction pattern of aligned C18-(PEPAuM-ox)2 fibers reveals a cross-β 
architecture. The colored arrows correlate with the (c) integrated d-spacings of the XRD diffractogram. (c) Figure 
showing the strand-to-strand and sheet-to-sheet distances as revealed via XRD. 
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The CD, FTIR, and XRD data revealed that the peptide-based core of the assemblies is 
stabilized by substantial β-strand formation, but the location of the β-strand within the peptide is 
uncertain. To address this, we applied ssNMR to site-specifically labeled C18-(PEPAuM-ox)2 
assemblies. To probe the very N-terminal end of the peptide, we applied 13C, 15N-labeling to the 
A1 residue. To probe the Pro-rich C-terminal half of the peptide, we also included in the same 
peptide a 13C, 15N-labeled P10 (Figure 3.24a). Figure 3.24b shows a 2D magic-angle spinning 
(MAS) ssNMR spectrum obtained for labeled C18-(PEPAuM-ox)2 assemblies. The off-diagonal 
cross-peaks provide residue-specific assignments of each labeled residue. The P10 peaks (black 
dashed lines) have chemical shifts indicative of a PPII helix structure (Figure S3.65a).118-119 The 
observation of a single set of peaks shows that P10 has the same PPII structure in all the C18-
(PEPAuM-ox)2 in the sample. In contrast, A1 features multiple sets of peaks, indicating the 
presence of multiple structures. The dominant A1 peaks (A1a and A1b), accounting for ~90% of 
the signal, have chemical shifts that indicate A1 to be part of the β-sheet structure (Figure 
3.24c). The A1c conformer is present at much lower intensity (~10% of the total signal), lacks β-
sheet shifts, and presumably reflects peptide that failed to incorporate into the amyloid-like core 
(e.g., the pseudospherical aggregates observed in TEM images). In long-mixing ssNMR data 
these three conformers show no sign of dynamics- or proximity-enabled polarization exchange 
(Figure S3.65b). Motion-sensitive ssNMR experiments (not shown) indicate that all sites are 
relatively rigid and immobilized in the peptide assemblies. Therefore, two structurally different 
peptide conformers, present at a 1:1 ratio, make up ~90% of the sample (Figure 3.24d). The 
ssNMR shows that the β-sheet structure extends to the very N-terminal residue A1. At the other 
end, P10 is outside the β-sheet, forming instead part of a PPII helix that presumably involves 
much of the Pro-rich C-terminal peptide end. We note a strong analogy to our studies of fibrillar 
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huntingtin exon1, which also has a peak-doubled amyloid core followed by a PPII-helical Pro-
rich domain.119 In that system the transition from β- to PPII-structure occurs over a single 
residue, making it reasonable that a similarly compact β-sheet/PPII-helix interface may occur 
here. 
 
 
Figure 3.24. MAS ssNMR results. (a) Position of residue-specific 13C-, 15N-labeling (arrows). (b) 2D 13C-13C MAS 
ssNMR of labeled C18-(PEPAuM-ox)2 assemblies. Dashed and colored lines connect sets of peaks from labeled P10 
(black dashed line) and A1 residues (solid lines). Three A1 conformations are marked with red (A1a), blue (A1b), 
and green (A1c) lines. (c) Secondary structure analysis of A1 ssNMR signals, showing A1a and A1b to be part of 
the β-sheet core. (d) Secondary structure distribution in the three peptide conformers observed by ssNMR, along 
with their relative ssNMR peak intensities (right). (e) Amyloid core model based on a class 3 steric zipper 
architecture. The compact Ala/Ser/Gly interface and the aromatic interface present intersheet distances of ~6.5 and 
~9 Å, respectively. Alternating peptides have distinct structures (blue/red coloring) that explain the observed peak 
doubling in the A1 β-sheet peaks. 
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How do two equally populated β-sheet/PPII peptide building blocks (Figure 3.24d) co-
assemble into the β-sheet-based core of our assemblies? The X-ray cross-β pattern showed ~6.5 
and ~9 Å inter-sheet distances between β-sheets. Sheet-to-sheet interfaces in amyloid structures 
have been characterized as ‘steric-zippers’ classified into distinct symmetry classes.120-121 The 
structural data, self-assembly behavior, and chemical nature of C18-(PEPAuM-ox)2 point to a likely 
architecture of the assemblies. The C18 acyl tails work to bring the peptides conjugates together 
to form micellar structures early in the assembly process. Clustering of the C18 tails dictates a 
parallel alignment of the self-assembling peptides and thus facilitates the formation of β-sheets 
that are co-aligned and parallel in nature. This fits well with our FTIR data and ssNMR results. 
Thus, these considerations restrict us to class 2 or class 3 type zipper motifs.120 Of these, only a 
class 3 zipper explains the doubled β-sheet ssNMR peaks and their 1:1 intensity ratio as it 
predicts structural differences between two types of co-assembling β-sheets. In addition, class 3 
zippers also predict the presence of two types of inter-sheet interfaces, which feature either the 
odd-numbered or the even-numbered residues (Figure 3.24e). The odd-residue interface features 
only small side chains (Ala/Ser/Gly), which enable the formation of a tight inter-sheet interface 
that places the sheets ~6.5 Å apart (Figure S3.65c). The even-numbered interface includes the 
large aromatic Tyr. In amyloid-like crystal structures with parallel β-sheets, such Tyr rings adopt 
a characteristic ring-stacked orientation, as shown in Figure S3.65d. The bulkiness of the 
aromatic rings causes notably wide sheet-to-sheet interfaces that are ~9-10 Å apart (e.g., Figure 
S3.65e), in line with the peptide assemblies’ X-ray pattern. Thus, this kind of assembly provides 
an elegant rationale for the ssNMR, FTIR, as well as X-ray results, and strongly argues for a 
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peptide core structure that combines packed PPII helical C-termini with a class 3 amyloid-like 
assembly. 
3.2.3 Single helix assembly model 
Taking into account the accumulated data on the C18-(PEPAuM-ox)2 assemblies, we propose a 
molecular packing model for the helical ribbon (Figure 3.25a). The ribbon consists of a 
monolayer of C18-(PEPAuM-ox)2 arranged perpendicular to the faces in a cross-β architecture. This 
allows the PPII helix and negatively charged carboxylates (at pH ~7) to be exposed on the outer 
surface of the helical ribbon. The model adheres to the ribbon vertical thickness constraint of ~4 
nm (labeled h in Figure 3.25a), as measured by AFM (vide supra); we estimate that the peptide 
length is ~3.8 nm (Figure S3.66). Since the extended length of C18-(PEPAuM-ox)2 is estimated to 
be ~7.5 nm (Figure S3.66), a bilayer structure where the alkyl chains are interdigitated in the 
core of the ribbon would not be possible. We speculate that the aliphatic chains, which are 
relatively ordered (vide supra), aggregate with one another at the inner surface of the helical 
ribbon or possibly fold inward with one another in-between β-sheets and therefore make only a 
small contribution to the measured ribbon thickness.38 In either case, the helical ribbon 
architecture segregates the relatively hydrophobic N-terminus from the aqueous buffer while 
exposing the hydrophilic C-terminus.122 This is in contrast to a twisted ribbon structure where 
both sides of the tape would be equally exposed. The ribbon width, w, is determined by the 
number of β-sheets stacked side-by-side with regular ~6.5 and ~9 Å distances. 
Based on this assembly model and the structural parameters of both the single helices and 
C18-(PEPAuM-ox)2 fibers, we conclude that the gold nanoparticles decorate the outer face of the 
helical ribbon (Figure 3.25b-d). Careful inspection of the nanoparticle orientation within the 
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superstructures (Figure 3.25c) indicates that the rod-like particles align in parallel along the 
width of the ribbons, which supports a model where particle growth proceeds in one direction 
(Figure 3.25d) and could be limited by the width of the helical ribbon. The regular distances 
between the particles could be due to electrostatic repulsion between particles.28 
 
 
Figure 3.25. Single helix assembly model. (a) Proposed assembly model of C18-(PEPAuM-ox)2 helical ribbons. β-
sheets run along the length of the fiber (interstrand distance = 4.6 Å). The width of the ribbon, w, is determined by 
the number of stacked β-sheets with lamination spacings of ~6.5 and ~9 Å. PPII helices are exposed at the outer 
surface of the helical ribbon. The blue and red layers correspond to the type ‘a’ and type ‘b’ β-sheets, respectively, 
shown in Figure 3.24. The aliphatic tails have been omitted for clarity. (b) AFM (amplitude image) and (c) TEM 
image aligned to highlight the structural similarity between the fiber assembly and nanoparticle assembly, alongside 
(d) the proposed single helix assembly model with gold nanoparticles bound to the outer face of the helical ribbon. 
The arrows show directionality similarities of the nanoparticle orientation. 
 
Since we propose that the C-termini of C18-(PEPAuM-ox)2 are exposed at the outer face of 
the helical ribbon, we reason then that the particles must be bound to the residues that make up 
the PPII helix. Previous reports on PEPAu binding onto gold surfaces conclude that Y2 and F12 
bind most strongly to the 111 facets of gold nanoparticles due to their aromatic side chains.94-96 
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Since the Y2 molecules are integral to the parallel β-sheet structure within the core of the peptide 
ribbon, the exposed phenylalanine at the C-terminus must account for much of the binding 
between the gold particles and the peptide assembly. In addition, methionine residues, which also 
bind strongly, could contribute to the overall binding interaction.96 The inner surface of the 
helical ribbon is sterically hindered, which prevents particle binding. 
3.3 CONCLUSION 
We have demonstrated that C18(PEPAuM-Ox)2 directs the formation of well-defined single-helical 
gold nanoparticle assemblies having strong plasmonic chiroptical activity that ranks among the 
highest observed for comparable systems. In addition, we proposed a molecular assembly model 
based on data acquired from several characterization techniques that is consistent with the 
structural parameters of the single helices. This model provides foundational information for 
understanding how peptide conjugate molecules constructed from inorganic-binding peptides can 
simultaneously self-assemble and bind to inorganic nanoparticles, thus enabling the assembly of 
nanoparticles into intricate superstructures. Moreover, this model serves as a launching point for 
rigorous rational design of new peptide conjugates for directing and precisely controlling 
nanoparticle assembly structures and metrics. Collectively, the results presented herein underline 
the utility of peptide constructs as building blocks for directing the assembly of nanoparticles 
into highly complex and well-defined nanoscale superstructures. Finally, they point toward 
future studies aimed at incorporating specific chemical modifications to the peptide side chains 
(e.g., oxidation, hydroxylation, phosphorylation, and glycosylation) and understanding how and 
why these modifications lead to morphological changes to a nanoparticle superstructure. 
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3.4 EXPERIMENTAL SECTION 
3.4.1 General materials and methods 
All chemicals were purchased from either Aldrich or Fisher and used without further 
purification. N3-C4H8CO-AYSSGAPPMPPF (N3-PEPAu) was synthesized by Pierce 
Biotechnology, Inc. Triethylammonium acetate buffer (TEAA) was purchased from Aldrich 
(catalog number 90358) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.3) 
(HEPES) buffer was purchased from Fisher (catalog number BP 299-100). Chloroauric acid 
(HAuCl4) was purchased from Aldrich (catalog number 520918). Peptide conjugates were 
purified using an Agilent 1200 series reverse-phase high-pressure liquid chromatography 
(HPLC) instrument equipped with an Agilent Zorbax 300SB-C18 column. Peptide conjugates 
were quantified based on their absorbance at 280 nm and using the extinction coefficient for 
tyrosine (1280 M-1cm-1). UV-vis spectra were collected using an Agilent 8453 UV-vis 
spectrometer equipped with deuterium and tungsten lamps. Matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry (MALDI-TOF MS) data were collected using an 
Applied Biosystem Voyager System 6174 MALDI-TOF mass spectrometer (positive reflector 
mode; accelerating voltage: 20 kV) and using α-cyano-4-hydroxycinnamic acid (CHCA) as the 
ionization matrix. TEM images were collected with a FEI Morgagni 268 (80 kV) with an AMT 
side mount CCD camera system. Phosphotungstic acid (pH 7.4) was used to stain TEM sample 
grids for the peptide assembly studies. TEM samples were prepared by drop-casting 6 μL of 
solution onto a 3 mm diameter copper grid coated with formvar. After 5 min., the excess solution 
was wicked away. The grid was washed with NP H2O (6 μL) and wicked away after 1 min. 
Attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy data were 
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collected on a PerkinElmer Spectrum 100 FTIR instrument with a universal attenuated total 
reflectance sampling accessory coupled to a computer using PerkinElmer Spectrum Express 
software. The sample was background-corrected in air. C18-(PEPAuM-ox)2 was dissolved and 
sonicated in 0.1 M HEPES (75μM). After 1 day, the assembled fibers were dialyzed three times 
in nanopure water using d-tube dialyzers (Millipore, catalog number 71505-3) to remove the 
buffer, and the fibers were concentrated. The concentrated solution containing the fibers were 
then drop-cast onto the ATF-FTIR substrate and allowed to air-dry. Nanopure water (NP H2O, 
18.1 MΩ) was obtained from a Barnstead DiamondTM water purification system. 
3.4.2 Preparation of N3-PEPAuM-ox 
N3-PEPAu (3 mg, 2.23 μmol) was dissolved in a 1:1 mixture of CH3CN/NP H2O. To this solution 
was added concentrated H2O2 to bring the final H2O2 concentration to 100 mM. The solution was 
vortexed and left undisturbed for 8-15 h. This final solution was purified using reverse-phase 
HPLC eluting with a linear gradient of 0.05% formic acid in CH3CN and 0.1% formic acid in NP 
H2O (5/95 to 95/5 over 30 min.). 
3.4.3 Preparation of C18-(PEPAuM-ox)2 
Alkyne-terminated aliphatic substrates and peptide conjugates were prepared according to 
protocols detailed in a previous report.62 
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3.4.4 Preparation of single helices 
In a plastic vial, C18-(PEPAuM-ox)2 (~18.7 nmol) was dissolved in 250 μL of 0.1 M HEPES buffer 
and sonicated for 5 min. After sonication, the solution was allowed to sit at room temperature for 
25 min. A fresh stock solution of HAuCl4 in TEAA buffer was prepared by mixing 100 μL of 0.1 
M HAuCl4 in NP H2O with 100 μL of 1 M TEAA buffer. The resulting mixture was vortexed for 
1 min. To the C18-(PEPAuM-ox)2 solution was added 2 μL of the freshly prepared HAuCl4/TEAA 
solution. A “dark cloud” appeared 2-4 s after the addition of the HAuCl4/TEAA solution; at this 
point, the vial was briefly vortexed and then left undisturbed at room temperature. 
3.4.5 Preparation of C18-(PEPAuM-ox)2 fibers 
75 μM solutions of C18-(PEPAuM-ox)2 fibers were prepared in 0.1 M HEPES buffer. For CD 
spectroscopy studies, 10 mM HEPES buffer was used. After 1 day of sitting at room 
temperature, the solutions were analyzed. For some CD and TEM experiments, CaCl2 was added 
(1 mM final concentration) to accelerate fiber formation. 
3.4.6 Cryogenic electron tomography and 3D reconstruction 
For the single-helical gold nanoparticle superstructure, 4 μL of solution was applied to the 
carbon side of glow discharged perforated R2/2 Quantifoil grids (Quantifoil Micro Tools, Jena, 
Germany) before plunge-freezing using a manual gravity plunger. A series of images were 
recorded by tilting the specimen from -60 to 70° in increments of 3° (<45°) and 2° (>45°). 
Images were recorded on a FEI Falcon II direct electron detector camera at a nominal 
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magnification of 39 000x. Altogether, 51 images were collected in one tilt series with a total dose 
of ~ 50 e-/Å2. Images were recorded at a defocus value of ~0.5 μm using FEI batch tomography 
software. The IMOD package123 was used to align tilted projection images and reconstruct the 
final 3D density map from the aligned image stack. For surface rendering, the tomogram was 
filtered to 20 Å resolution and displayed using the program UCSF CHIMERA.124 
3.4.7 Atomic force microscopy 
AFM images were collected with an Asylum MFP-3D atomic force microscope using tapping-
mode. Images were obtained using ultrasharp AFM tips (NanoandMore, SHR-150), with a 1 Hz 
scanning rate. The APTES-mica was prepared by drop-casting a 0.1% APTES solution in NP 
H2O onto freshly cleaved mica, and after 10 min., the mica was rinsed with NP H2O. C18-
(PEPAuM-ox)2 was dissolved in 0.1 M HEPES (75 μM) and allowed to sit at room temperature 
overnight. After 1 day of incubation, 20 μL of the solution was drop-cast onto the APTES-
functionalized mica. After 1 min., the sample was rinsed with NP H2O and allowed to air-dry 
overnight. 
3.4.8 Circular dichroism spectroscopy 
CD measurements were conducted on an Olis DSM 17 CD spectrometer. The scan rate was 8 
nm/min., and the bandwidth was 2 nm. All CD experiments were carried out in 10 mM HEPES 
(peptide assembly; 200 -280 nm) or 0.1 M HEPES (nanoparticle assembly; 450-800 nm) with a 1 
mm path length quartz cuvette at 25°C. 
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3.4.9 Powder X-ray diffraction 
Powder X-ray diffraction was performed on a Bruker X8 Prospector Ultra diffractometer 
equipped with an APEX II CCD detector and an IμS microfocus Cu Kα source (λ = 1.54178 Å). 
The diffractograms were recorded at a distance of 15 cm at room temperature. Raw data were 
retrieved using the PILOT plug-in in the Bruker APEX II software package and further 
processed in Match! software to obtain d and intensity values. The sample was prepared by 
dissolving ~1.5 mg of C18-(PEPAuM-ox)2 in 1 mL of 0.1 M HEPES and sonicating for 5 min. The 
sample was left to sit overnight. After 24 h, the solution was ultracentrifuged (rmax = 213 000g) 
for 1 h. The supernatant was removed and NP H2O (1 mL) was added, and the sample was 
ultracentrifuged again at the same speed. After centrifugation, the supernatant was removed, 
leaving behind a clear gel. The peptide gel was loaded into a glass capillary (φ = 0.7 mm) and 
air-dried. 
3.4.10 MAS solid-state NMR spectroscopy 
Labeled N3-PEPAu was purchased from Pierce Custom Peptides, and labeled C18-(PEPAuM-ox)2 
was synthesized according to the protocols detailed above. Labeled C18-(PEPAuM-ox)2 fibers (~2 
mg) were packed into thin-wall 3.2 mm zirconia MAS rotors (Bruker Biospin, Billerica, MA) by 
ultracentrifugation at ~175 000g in a home-built sample packing tool spun in a Beckman Coulter 
Optima L-100 XP ultracentrifuge equipped with a SW-32 Ti rotor. MAS ssNMR spectra were 
obtained with a widebore Bruker Avance I NMR spectrometer operating at a 1H Larmor 
frequency of 600 MHz (14.1 T) using a 3.2 mm HCN MAS ssNMR probe equipped with a 
“EFree” reduced electric field coil (Bruker Biospin). Sample temperature was maintained at 277 
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K using a constant flow (800 L/h) of cooled gas. Bruker Topspin software was used to acquire 
the spectra. Spectra were processed using NMRPipe software and analyzed with 
CCPNMR/Analysis.125-126 The 13C signals of adamantine were used to externally reference 
chemical shifts to 4,4-dimethyl-4-silapentane-1-1 sulfonic acid (DSS).127 1D and 2D ssNMR 
spectra were acquired at 10 kHz MAS, using ramped 1H, 13C cross polarization (CP) with a 2.0 
ms CP contact time, a 3 s recycle delay, and 83 kHz two-pulse phase-modulated (TPPM) 
decoupling.128 A total of 1024 scans were obtained for the 1D Cp Experiment. The short-mixing 
13C-13C 2D spectrum was obtained with 20 ms of dipolar assisted rotational resonance (DARR) 
13C-13C mixing. The 2D spectrum in Appendix B (Figure S3.65b) feature 500 ms of 13C-13C 
proton-driven spin diffusion (PDSD), which is expected to allow longer-range signal transfer 
over up to 6-7 Å.129 Additional experimental details are summarized in Table S3.2 of Appendix 
B. 
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4.0  POST-SYNTHETIC SURFACE MODIFICATION OF HOLLOW SPHERICAL 
GOLD NANOPARTICLE SUPERSTRUCTURES WITH TUNABLE ASSEMBLY 
METRICS 
This work is a manuscript in preparation. The supporting information for this chapter is found in 
Appendix C. 
4.1 INTRODUCTION 
As mentioned in Chapter 1, metallic nanoparticles and their assemblies have attracted significant 
attention due to their myriad properties and applications. An important component of metallic 
nanoparticles is the ligand that is adsorbed to the nanoparticle surface. They serve a variety of 
important roles: i) they passivate the nanoparticle surface, preventing aggregation; ii) they can 
impart functionality to the nanoparticle; iii) they serve as the interface between the nanoparticle 
and its environment; and iv) they can significantly affect the physical properties of the 
nanoparticle core. To date, hundreds of ligands have been successfully employed to introduce 
new properties and functions to nanoparticles, giving rise to a plethora of applications.130 For 
example, gold nanoparticles that have a shell of oligonucleotide ligands anchored onto their 
surface exhibit unique cellular uptake properties, which make them attractive therapeutic 
candidates.131 Motivated by the important role that ligand chemistry plays in nanoparticle-based 
 61 
systems, we aimed to explore methods to modify the surfaces of pre-fabricated nanoparticle 
superstructures. To our knowledge, post-synthetic modification of nanoparticle assemblies has 
been relatively unexplored. Most nanoparticle self-assembly methods use nanoparticles anchored 
with thiolated ligands (e.g., thiolated oligonucleotides, thiolated amphiphilic block copolymers) 
to direct their assembly,13, 21-22, 132-137 which make them poor candidates for post-synthetic 
modification (via ligand exchange) due to the relatively strong gold-thiol bond.  
In contrast to other nanoparticle assembly methods, the Rosi group has developed a 
peptide-based route for assembling gold nanoparticle superstructures.25 In this method, a gold-
binding peptide conjugate, R-PEPAu (where R = hydrophobic organic group, and PEPAu = 
AYSSGAPPMPPF55), both caps and directs the assembly of gold nanoparticles.25 The peptide 
assembly serves as the underlying scaffold that supports the nanoparticle superstructure.25, 62-63 
We propose that the amino acid residues near the C-terminus of PEPAu are responsible for much 
of the binding between the particle and the peptide assembly,63 which is in agreement with 
computational studies.96 We postulate that the peptides that incorporate into the peptide assembly 
scaffold bind to part of the gold nanoparticles, anchoring them to the structure,63 while a 
combination of free, unincorporated peptide conjugate molecules and buffer constituent 
molecules (e.g., HEPES, which is a weak binding agent138) in solution help stabilize the solvent-
exposed nanoparticle surface. We reason then that the portion of the nanoparticles making up the 
superstructure that are exposed to solution could be replaced by more strongly binding surface 
capping ligands via ligand exchange and that such ligand exchange methods may provide a 
means of tailoring the properties of the superstructure. As a proof-of-concept, we chose to 
conduct these post-synthetic modification studies on hollow spherical gold nanoparticle 
(HSAuNP) superstructures that were previously assembled and studied by our group.60, 64, 139 
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These superstructures were chosen because i) they have a propensity to aggregate, which limits 
their potential utility in various applications; ii) they are spherical and we envision that they can 
ultimately be used as a ‘supernanoparticle’ which could constitute a complex building block for 
extended periodic lattices; and iii) they have properties that make them attractive as therapeutics 
agents8, 12-13, 134, 140-141 and metamaterials.142-144 Herein, we describe post-synthetic methods to 
functionalize the surfaces of HSAuNP superstructures. We show that the superstructures can be 
stabilized and their surface properties manipulated. These results offer a glimpse of the potential 
of using these methods to modify the surface properties of a variety of different nanoparticle 
superstructures. 
4.2 RESULTS AND DISCUSSION 
4.2.1 Monitoring the assembly formation of HSAuNP superstructures 
As opposed to other methods where particles are pre-fabricated prior to assembly, our assembly 
methodology is unique in that the gold nanoparticles are synthesized and directed into the 
nanoparticle superstructure in one concerted step.25 This process is highly dynamic in that the 
structural features of the superstructure evolve throughout the assembly process. Therefore, we 
first began by studying the formation of HSAuNP superstructures over time with varying 
amounts of gold precursor solution added to the assembly solution. We hypothesized that 
varying the amount of gold precursor solution to the assembly medium would be a 
straightforward approach to adjust the density of nanoparticles bound to the peptide surface and 
therefore would serve as a means to control their optical properties. We used a modified version 
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of a protocol developed in our lab (see experimental section for details).60, 64 Briefly, 0.7, 0.9, 
and 1.1 μL of a mixture of chloroauric acid (HAuCl4) and triethylammonium acetate (TEAA)  
(0.1 M HAuCl4 in 1 M TEAA), which serves as the gold precursor solution, was added to 
solutions of C6-AA-PEPAu in 0.1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) buffer (150 μM).  In this method, HEPES functions as the primary reducing agent for 
the HAuCl4/TEAA mixture, promoting the in situ synthesis of gold nanoparticles, and C6-AA-
PEPAu functions as the directing agent for nanoparticle assembly. The resulting assemblies were 
monitored via transmission electron microscopy (TEM) at multiple different time points (10 
min., 30 min., 1 hr., 3 hrs., and 1 day). 
 From TEM, HSAuNP superstructures were observed after 10 min. for all samples 
(Figure S4.67). The superstructures were well-dispersed with few small particles bound to the 
peptide assembly surface. Samples prepared after 30 min. revealed structures with a greater 
number of particles adhered to the spherical peptide assembly (Figure 4.26a,e,i). After 1 hr., 
more particles attach to the peptide assembly but to a varying extent depending on the amount of 
HAuCl4/TEAA introduced (Figure 4.26b,f,j). HSAuNP superstructures with the highest density 
of nanoparticles were observed for samples injected with 1.1 μL of gold precursor solution 
(Figure 4.26j), whereas decreasing nanoparticle coverage was observed for the solutions 
injected with 0.9 and 0.7 μL of the gold precursor solution, respectively. (Figure 4.26f,b). These 
results confirm our hypothesis that the nanoparticle density of the HSAuNP superstructures can 
indeed be tuned simply by adjusting the amount of gold precursor solution added to the assembly 
mixture. Well-dispersed HSAuNP superstructures were observed after 3 hrs. of assembly 
(Figure 4.26c,g,k). At this point, however, we noticed few small clusters of assemblies, 
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suggesting the onset of aggregation between the nanoparticle superstructures (Figure 4.26c,g,k). 
Extensive aggregation was observed after 24 hrs. (Figure 4.26d,h,l).  
 
 
Figure 4.26. TEM images of HSAuNP superstructures assembled with 0.7 uL HAuCl4/TEAA after (a) 30 min., (b) 
1 hr., (c) 3 hrs., and (d) 24 hrs. TEM images of HSAuNP superstructures assembled with 0.9 uL HAuCl4/TEAA 
after (e) 30 min., (f) 1 hr., (g) 3 hrs., and (h) 24 hrs. TEM images of HSAuNP nanoparticle superstructures 
assembled with 1.1 uL HAuCl4/TEAA after (i) 30 min., (j) 1 hr., (k) 3 hrs., and (l) 24 hrs. (scale bars = 100 nm) 
  
 The propensity for aggregation at later time points could be due to the absence of capping 
ligands, which are necessary for passivating the gold nanoparticle surface. At initial time points, 
unincorporated C6-AA-PEPAu monomers in solution may serve to temporarily cap the 
nanoparticle superstructures; however, as the assembly progresses, C6-AA-PEPAu monomers 
incorporate into the spherical peptide assemblies, thus depleting the population of C6-AA-PEPAu 
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monomers in the assembly medium. This depletion may initiate the aggregation of the 
nanoparticle superstructures. In fact, the average HSAuNP superstructure diameter, measured via 
TEM, increases during the assembly process (Figure 4.27a). This could be due to an Ostwald 
ripening-like effect, where larger, more stable HSAuNP superstructures continue to grow at the 
expense of smaller ones. Interestingly, collected data on the diameters of HSAuNP 
superstructures formed with 0.7, 0.9, or 1.1 μL revealed a distinctive trend: smaller diameters are 
observed when larger amounts of HAuCl4/TEAA is introduced to the assembly solution (Figure 
4.27b). We attribute this trend to the amount of cationic gold ions present in the assembly 
solution. These ions can initiate peptide nucleation events that lead to peptide assembly.82 
Therefore, we reason that larger concentrations of gold ions lead to more nucleation events, 
which results in smaller HSAuNP superstructures on average.145 These results show that one can 
tune the superstructure size by adjusting the amount of gold precursor solution added to the 
assembly mixture. 
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Figure 4.27. (a) Distribution of sphere diameters of HSAuNP superstructures after 10 min., 1 hr. and 3 hrs. for 
samples assembled with 1.1 μL of HAuCl4/TEAA. (b) Distribution of sphere diameters (collected after 1 hr. of 
assembly time) as a function of the amount of HAuCl4/TEAA added to the C6-AA-PEPAu solution in HEPES.  
4.2.2 Ligand-capped nanoparticle superstructures 
Based on the assembly formation studies, we hypothesized that introduction of capping ligands 
immediately before the onset of aggregation could stabilize the HSAuNP superstructures, thus 
preventing their aggregation. Since prior work has shown that PEPAu can effectively cap the 
surface of gold nanoparticles,55 we introduced an excess amount of PEPAu (4.7 nmol) to 
HSAuNP superstructures formed after 1 hr. of assembly with 0.7 μL and 1.1 μL of 
HAuCl4/TEAA added. After 24 hrs., well-dispersed HSAuNP superstructures were observed, 
indicating that PEPAu successfully passivated the nanoparticle superstructure surface (Figure 
4.28a,b). UV-Vis spectra of these superstructures revealed a LSPR band at ~540 nm for both 
assemblies, which is consistent with particles that are in close proximity with one another 
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(Figure 4.28c,d). We also note that the nanoparticle coverage density between the 
superstructures formed with 0.7 and 1.1 μL HAuCl4/TEAA remained consistent with our prior 
results in that the former had lower coverage of nanoparticles compared to the latter. As 
expected, the diameters of the individual gold nanoparticles increased, indicating that excess 
gold ions in solution continue to reduce onto the nanoparticles. 
 
 
Figure 4.28. TEM images of HSAuNP superstructures formed with (a) 0.7 μL and (b) 1.1 μL of HAuCl4/TEAA, 
after 1 day of incubation with PEPAu, and (c,d) their corresponding UV-Vis absorption spectra, respectively. TEM 
images of HSAuNP superstructures formed with (e) 0.7 μL and (f) 1.1 μL of HAuCl4/TEAA after 1 day of 
incubation with proteinase K, and (g,h) their corresponding UV-Vis absorption spectra, respectively. 
 
 While PEPAu served to maintain the dispersion of the HSAuNP superstructures, upon 
centrifugation, the superstructures aggregated (not shown). This is not surprising considering the 
relatively weak peptide-nanoparticle binding interaction. Furthermore, incubation of PEPAu-
capped spheres in the presence of proteinase K, a non-specific peptidase, led to aggregation, but 
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in agreement with a prior study, the HSAuNP superstructure themselves remained intact (Figure 
4.28e,f).139 UV-Vis spectra showed a sizeable red-shift confirming the aggregated product 
(Figure 4.28g,h). We conclude that the PEPAu capping layer used to prevent aggregation was 
digested by the peptidase, but the C6-AA-PEPAu molecules that make up the peptide-gold 
nanoparticle superstructure remain intact, suggesting that the peptides within the structure are 
highly compact and resistant to proteinase K digestion. These studies suggest that one can 
exploit the different binding properties between “core” peptide molecules (i.e., C6-AA-PEPAu 
molecules that make up the peptide assembly scaffold) and “surface” peptide molecules (i.e., 
PEPAu molecules that passivate the solvent-exposed nanoparticle surface), as hypothesized. 
Motivated by the promising results of PEPAu-capped nanoparticles superstructures and 
the stability exhibited by C6-AA-PEPAu molecules that make up the spherical peptide assembly 
scaffold, we began to explore the possibility of functionalizing the surfaces of HSAuNP 
superstructures. We first employed thiolated ligands. Two common thiolated ligands used for 
functionalizing gold nanoparticles, mercaptohexanoic acid (MHA) and poly(ethylene glycol) 
methyl ether thiol (PEG-SH; Mn = 1000 Da), were chosen. Since thiols form a strong bond with 
gold, we predicted that the presence of thiolated capping ligands may affect the structural 
integrity of the HSAuNP superstructures; therefore, we investigated how varying amounts of 
added ligand affects the nanoparticle superstructure integrity. After 30 min. of assembly, stock 
solutions of MHA and PEG-SH were added directly to solutions of HSAuNP superstructures 
(formed using 1.1 μL HAuCl4/TEAA) to give final thiol concentrations of 2, 20, and 200 μM. 
TEM samples were prepared after 24 hrs. of incubation (Figure 4.29). 
Well-dispersed HSAuNP superstructures were observed only under certain conditions. At 
very low MHA concentrations (2 μM), aggregated superstructures were the dominant product 
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(Figure 4.29a). However, at intermediate MHA concentrations (20 μM), the superstructures 
remained dispersed (Figure 4.29b). At higher MHA concentration (200 μM), only a few 
dispersed superstructures were observed indicating that a majority of the HSAuNP 
superstructures degraded (Figure 4.29c). Based on this data set, we conclude that there is a 
minimum threshold thiol concentration that is needed to disperse the spheres, but there is also a 
maximum amount of added thiol that the spheres can tolerate, beyond which they deconstruct. 
For HSAuNP superstructures incubated with PEG-SH, we observed dispersed superstructures for 
spheres incubated in 2 and 20 μM PEG-SH solutions (Figure 4.29d,e), but degraded 
superstructure and free nanoparticles were observed in 200 μM PEG-SH (Figure 4.29f). The 
discrepancy between MHA and PEG-SH at low concentration (2 μM) is most likely due to the 
steric difference between the two molecules. PEG-SH, which is much more sterically bulky than 
MHA, would have less ligand density than MHA on the nanoparticle surface, and therefore can 
stabilize the nanoparticle superstructure at lower thiol concentrations.146 In addition to dispersed 
HSAuNP superstructures, there appeared to be a greater concentration of free nanoparticles with 
increasing amount of added thiol. This may be attributed to i) the reduction of free gold ions in 
solution by the thiol ligands or ii) possibly the deconstruction of some HSAuNP superstructures. 
Based on these studies we conclude that thiolated ligands can indeed be used to effectively cap 
the surface of pre-fabricated nanoparticle superstructures, assembled using our peptide-based 
method, provided that certain controlled amounts of thiolated ligands are added. Beyond a 
certain threshold amount, the thiolated ligands can displace/disrupt the peptide assembly-gold 
nanoparticle ‘bonds’, and thus promote the assembly deconstruction (Figure 4.29c,f). 
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Figure 4.29. TEM images of HSAuNP superstructures after 1 day of incubation in (a) 2 μM, (b) 20 μM, and (c) 200 
μM MHA. TEM images of HSAuNP superstructures after 1 day of incubation in (d) 2 μM, (e) 20 μM, and (f) 200 
μM PEG-SH (MW = 1000). (scale bars = 200 nm) 
4.3 CONCLUSION AND FUTURE WORK 
In conclusion, we demonstrate that the surface of HSAuNP superstructures can be modified 
through addition of capping ligands during the nanoparticle assembly process. We show that for 
thiolated ligands, there is an optimum concentration needed to disperse the assemblies and 
prevent degradation of the superstructures. These studies show that the peptide assembly-gold 
nanoparticle ‘bonds’ are robust and ligand exchange can take place only on the surface-exposed 
portion of the nanoparticles. These results highlight a powerful and versatile post-synthetic 
approach for tuning the surface chemistry and properties of nanoparticle superstructures. We also 
show that the assembly metrics, such as nanoparticle coverage density and size, can be tuned by 
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simply adjusting the amount of gold precursor mixture introduced into the assembly solution. 
Future work will be directed toward extending these methods by expanding the repertoire of 
ligands attached to the nanoparticle superstructure (e.g., thiolated oligonucleotides), as well as 
translating this post-synthetic modification method to other peptide-based nanoparticle 
superstructures that have been developed by our group, such as optically active single helices. 
4.4 EXPERIMENTAL SECTION 
4.4.1 General materials and methods 
N3-C4H8CO-AYSSGAPPMPPF (N3-PEPAu) was synthesized and purified by Pierce 
Biotechnology, Inc. AYSSGAPPMPPF was synthesized and purified by New England Peptide 
Inc. Triethylammonium acetate buffer (TEAA) was purchased from Aldrich (catalog number 
90358) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.3) (HEPES) buffer was 
purchased from Fisher (catalog number, BP 299-100). Chloroauric acid (HAuCl4) was purchased 
from Aldrich (catalog number, 520918). Poly(ethylene glycol) methyl ether thiol (PEG-SH, 
average Mn = 1000 Da) was obtained from Laysan Bio, Inc. 6-Mercaptohexanoic acid (MHA) 
was obtained from Aldrich (catalog number, 674974). Peptide conjugates were purified using an 
Agilent 1200 series reverse-phase high-pressure liquid chromatography (HPLC) instrument 
equipped with an Agilent Zorbax 300SB-C18 column. Peptide conjugates were quantified based 
on their absorbance at 280 nm and using the extinction coefficient for tyrosine (1280 M-1cm-1). 
UV-Vis spectra were collected using an Agilent 8453 UV-vis spectrometer equipped with 
deuterium and tungsten lamps. TEM images were collected with a FEI Morgagni 268 (80 kV) 
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with an AMT side mount CCD camera system. TEM samples were prepared by drop-casting 5 
μL of solution onto a 3 mm diameter copper grid coated with formvar. After 4 min., the excess 
solution was wicked away. The grid was stained with phosphotungstic acid solution (pH = 7.4, 5 
μL) and wicked away after 1 min. Nanopure water (NP H2O, 18.2 MΩ) was obtained from a 
Barnstead DiamondTM water purification system. 
4.4.2 Assembly of HSAuNP superstructures 
We use a protocol that is similar to the protocols used previously within the group.60, 64 In a 
plastic vial, lyophilized C6-AA-PEPAu (~18.7 nmol) was dissolved in 125 μL of 0.1 M HEPES 
buffer and sonicated for 5 min. After sonication, the solution was allowed to sit at room 
temperature for 30 min. During the 30 min. incubation time, a fresh gold precursor solution was 
prepared: a mixture of 0.1 M chloroauric acid (HAuCl4) in 1 M triethylammonium acetate 
(TEAA; pH = 7.0) buffer was vortexed for 1 min. and incubated for 10 min. at room 
temperature. Thereafter, the supernatant of the mixture was centrifuged for 10 min. at 5k rpm. 
After the 30 min. 0.7-1.1 μL of the freshly prepared HAuCl4/TEAA solution was added to the 
peptide solution. A “dark cloud” appeared 2-4 s after the addition of the HAuCl4/TEAA solution; 
at this point, the vial was briefly vortexed and then left undisturbed. 
4.4.3 PEPAu-capped HSAuNP superstructures 
125 μL solutions of HSAuNP superstructures (formed using 0.7 μL, and 1.1 μL HAuCl4/TEAA) 
were synthesized according to the protocol detailed above. After 1 hr. of assembly time, the 
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solution was transferred to a vial containing lyophilized PEPAu (4.7 nmol). The solution was 
mixed briefly and left undisturbed at room temperature. 
4.4.4 Proteinase K stability studies 
The experimental protocol for the proteinase K stability studies was conducted previously in our 
group.139 Briefly, 5 μL of 20 mg/mL proteinase K was added to as-synthesized PEPAu-capped 
spherical gold nanoparticle superstructures. The mixtures were incubated at 37°C for up to 24 
hrs. 
4.4.5 Thiol-capped HSAuNP superstructures 
To 125 μL solutions of as-synthesized HSAuNP superstructures (after 20 min. of assembly time; 
formed using 1.1 μL HAuCl4/TEAA) was added 1 μL of 0.1 mM MHA/PEG-SH, 1 μL of 1 mM 
MHA/PEG-SH, or 10 μL of 1 mM MHA/PEG-SH stock solutions to make a 2, 20, or 200 μM 
solution concentration of MHA/PEG-SH, respectively. The solutions were vortexed briefly and 
allowed to sit at room temperature for 24 hrs. 
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5.0  PEPTIDE-OLIGONUCLEOTIDE CHIMERAS (POCS): PROGRAMMABLE 
BIOMOLECULAR CONSTRUCTS FOR THE ASSEMBLY OF MORPHOLOGICALLY-
TUNABLE SOFT MATERIALS 
This work, written in collaboration with Ryan V. Thaner, Soumitra Mokashi Punekar, SonBinh 
T. Nguyen*, and Nathaniel L. Rosi*, is under revision. The supporting information for this 
chapter is found in Appendix D. 
Dr. Ryan V. Thaner prepared the azido-functionalized oligonucleotide starting material. 
Soumitra Mokashi Punekar assisted with the synthesis and purification of POCs and the 
assembly experiments. 
5.1 INTRODUCTION 
Few classes of material building blocks exhibit the programmability offered by nucleic acids and 
peptides, and from a material-assembly standpoint, each offers a distinct set of properties. 
Nucleic acids feature unrivalled site-specificity based on sequence-specific base-pairing 
interactions, which allows for the construction of highly intricate nanoscale architectures 
including DNA origami147-148 and spherical nucleic acid assemblies.20-21 Peptides have highly 
modular assembly and substrate-recognition capabilities, drawing from their rich diversity of 
amino acid sequences. For example, a 10-mer peptide built from natural amino acids can have 
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2010 possible sequences. It stands to reason then that molecular building blocks composed of both 
nucleic acids and peptides could assemble into materials that exhibit heretofore unobserved 
features and properties. 
Peptide-oligonucleotide chimeras (POCs), comprising interlinked peptides and 
oligonucleotides, represent a new, versatile class of building blocks having assembly 
characteristics and properties deriving from both biomolecular components. While biological 
applications of POCs have been explored,149-150 few studies have examined  their potential as 
programmable building blocks for the construction of soft materials.151-155 Herein, we present a 
modular synthesis of POCs in which the peptide and oligonucleotide are attached to an organic-
core molecule, resulting in a highly tunable assembly platform where both peptide and 
oligonucleotide “character” can be independently varied, akin to a block copolymer. The 
resulting POCs can assemble into either vesicles or 1D fibers, depending on the length of the 
oligonucleotide building block and the salt concentration. These results highlight the promise of 
POCs as a versatile class of soft material building blocks and point toward their use for the 
construction of responsive and dynamic functional materials. 
5.2 RESULTS AND DISCUSSION 
For this initial report, we focus our attention on a POC design that links a single peptide to a 
single oligonucleotide through a biphenyl organic core (Figure 5.30). The 
AAAYSSGAPPMPPF peptide sequence, was chosen based on its ability to assemble into 
various structures when conjugated to an organic molecule at its N-terminus.60 A,4,4’-
bisethynylbiphenyl organic core was used so that copper (I) catalyzed “click” chemistry could be 
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employed to covalently attach azido-modified peptides and oligonucleotides (Figure 5.30).80-81, 
156 Conjugation was achieved in a stepwise fashion:  1) the oligonucleotide, an azido-modified 
18- or 6-base sequence (Figure S5.68), was first attached to the biphenyl core using established 
solid-phase synthesis method;157 and 2) the peptide, an N-terminal azido-modified peptide (N3-
C4H8CO-AAAYSSGAPPMPPF) (Figure S5.69), was next attached in the solution phase to yield 
the POCs (Figure 5.30). Each POnC (n = 18, 6) was purified via reverse-phase high-performance 
liquid chromatography (HPLC) and their compositions were confirmed by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Figure S5.70). 
 
 
Figure 5.30. Modular synthesis of POCs: i) covalent attachment of an azido-modified oligonucleotide sequence to a 
biphenyl organic linker followed by ii) covalent attachment of an azido-modified peptide. 
 
 We first determined optimal conditions for PO18C assembly. In the absence of charge-
shielding cations, POCs resisted assembling in aqueous media due to the oligonucleotide’s 
negatively charged phosphate backbone. Countercation screening revealed that Ca+2 promotes 
assembly of PO18Cs into well-defined structures, which prompted a systematic study of PO18C 
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assembly as a function of [CaCl2]. 500 µM solutions of desalted and lyophilized PO18C (500 
µM) were prepared in aqueous CaCl2 solutions (10, 50, 150, and 300 mM). These solutions were 
heated to 80°C to denature any non-specific PO18C aggregation states and then cooled to room 
temperature to arrive at preferred assembled structures. Transmission electron microscopy 
(TEM) was used to image resulting assemblies. Defined circular structures were observed in 50 
mM CaCl2 (Figure 5.31b and Figure S5.71), whereas fibers were exclusively observed in 300 
mM CaCl2 (Figure 5.31d and Figure S5.73). In 150 mM CaCl2, a mixture of products was 
observed including circular/pseudo circular structures and fibers (Figure 5.31c and Figure 
S5.72). Few amorphous assemblies were observed at 10 mM CaCl2, indicating the existence of a 
threshold in salt concentration for assembly to occur (Figure 5.31a).  
 
 
Figure 5.31. PO18C assemblies at varying CaCl2 concentrations. TEM images of PO18C assemblies formed in (a) 10 
mM, (b) 50 mM, (c) 150 mM, and (d) 300 mM CaCl2. TEM samples were prepared after 15-20 hrs. of assembly 
time. 
 
 Scanning electron microscopy (SEM) and tapping-mode atomic force microscopy (AFM) 
were employed to further investigate the morphology of the circular structures formed in 50 mM 
CaCl2. SEM images suggest a spherical morphology, (Figure 5.32a) and AFM indicates 
vesicular structure, as the height profile traces are typical of collapsed hollow spheres (Figure 
5.32b-d and Figure S5.74).108, 158 In addition, phase images reveal different surface profiles 
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between the periphery and the interior (Figure 5.32e and Figure S5.75), which is likely due to 
the different deformation response of the sphere “center” and “edges”.108, 158 The thickness,  
measured via AFM,  of the fully collapsed spheres that were previously exposed to high-vacuum 
TEM environment, is approximately 30 nm (Figure S5.76), which is equal to twice the length of 
an extended PO18C (~15 nm; Figure S5.77). We therefore conclude that the sphere membrane 
consists of a single, flexible PO18C monolayer. 
 
 
Figure 5.32. PO18C assembly characterization. (a) SEM images of PO18C vesicles assembled in 50 mM CaCl2. (b) 
AFM image of PO18C vesicles deposited on mica. (c) AFM image of a vesicle and (d) corresponding height profile 
along the dashed line shown in c. (e) Phase image of the vesicle shown in c. (f) UV-Vis spectrum of free 15 nm gold 
nanoparticle functionalized with complementary O18 sequence (black line) and gold nanoparticle-decorated vesicles 
after addition of the complementary functionalized gold nanoparticles to a solution containing PO18C vesicles (red 
line). (g) TEM images of the gold nanoparticle-decorated vesicles after addition of 15 nm gold nanoparticles 
functionalized with complementary O18 to a solution of PO18C vesicles. (h) Proposed assembly model of PO18C 
vesicles. The vesicles are composed of a PO18C monolayer, with the oligonucleotides exposed on the outer surface. 
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 Because both the peptide and oligonucleotide are hydrophilic compared to the biphenyl 
organic core, either may be exposed at the outer surface of the PO18C spheres. To determine if 
the O18 block is exposed, we mixed the spheres with 15 nm gold nanoparticles decorated with 
oligonucleotides complementary to O18. Under conditions that promote hybridization, localized 
surface plasmon resonance (LSPR) band of the particles red shifts, signifying particle 
aggregation and assembly (Figure 5.32f), and TEM images show the gold nanoparticles adhered 
to the sphere surface (Figure 5.32g and Figure S5.78). Collectively, the results lead us to 
propose that the spheres consist of a single PO18C monolayer, with the peptide directed inward 
and the highly-charged oligonucleotide projected outward to the aqueous salt solution (Figure 
5.32h). These structures resemble ‘spherical nucleic acid’ (SNA) constructs, which have shown 
promise as therapeutic agents.131, 159-163 Unlike reported SNAs, however, the PO18C assemblies 
feature a hollow interior enclosed by a pliable, asymmetric monolayer membrane. Their unique 
composition and structure will motivate future studies aimed at exploration of their therapeutic 
potential. 
 As noted earlier, PO18Cs assemble into fibers in 150 mM and 300 mM Ca+2 solutions. 
These higher salt concentrations may facilitate tighter O18 packing, resulting in parallel 
alignment of the PO18Cs into fibers (Figure 5.33a).  In contrast, at lower salt concentrations (50 
mM), repulsive interactions between phosphate backbones would drive the oligonucleotides 
apart from one another, resulting in spherical assemblies (Figure 5.33b). Based on this 
reasoning, tuning the length of the oligonucleotide should significantly affect the assembly 
morphology. PO6C with a much shorter oligonucleotide portion than PO18C, may assemble into 
fibers at salt concentrations below 150 mM. 
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Figure 5.33. Role of charge shielding. (a) Greater charge shielding can allow for tighter packing of POCs, which 
can lead to fiber formation. (b) Greater repulsion due to less charge shielding favors the formation of vesicles. 
 
 Indeed, TEM images of PO6C assemblies show primarily twisted fibers and fiber 
aggregates at 50-300 mM CaCl2 (Figure 5.34b-d and Figure S5.80-S5.82). A mixture of 
spherical and fiber assemblies was observed at 10 mM CaCl2 concentration, which is also 
consistent with our hypothesis (Figure 5.34a and Figure S5.79). At higher ionic strengths (150 
and 300 mM Ca+2), the fibers appear to consist of several bundled strands (Figure 5.34c,d and 
Figure S5.81, Figure S5.82); however, individual fibers can be observed at lower ionic strengths 
(10 and 50 mM Ca+2) (Figure S5.83). The fibers were exposed to a solution of 5 nm gold 
nanoparticles functionalized with the O6-complementary sequence. However, the particles did 
not adhere to the fibers and no shift in the LSPR band was observed (Figure S5.84); this implies 
that the O6 within the fibers are packed tightly together and relatively inaccessible, which 
prevents duplex formation. Although we cannot propose a detailed model for POC assembly 
within the fibers at this stage, these results are not inconsistent with the highly-charged 
oligonucleotide block of the POC still being exposed to the aqueous assembly medium. In 
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summary, our results clearly demonstrate that both salt concentration and oligonucleotide length 
significantly affect the morphology of the POC assembly and that both can be independently 
tuned to promote either fiber or sphere assembly. 
 
 
Figure 5.34. PO6C assemblies at varying CaCl2 concentrations. TEM images of PO6C assemblies formed in (a) 10 
mM, (b) 50 mM, (c) 150 mM, and (d) 300 mM CaCl2. TEM samples were prepared after 15-20 hrs. 
 
 We also considered whether interpeptide interactions affect assembly behavior and 
morphology. In previous studies, we determined that the N-terminal portion of 
AYSSGAPPMPPF can assemble into β-sheets if a hydrophobic R-group is attached to the 
alanine residue.25, 63 We used Fourier-transformed infrared (FTIR) spectroscopy to determine if 
similar interpeptide interactions contribute to the assembly behavior of the POCs. An amide I 
band at 1642 cm-1, which indicates the absence of interpeptide secondary structure, was observed 
for PO18C spheres; in contrast, an amide I band at 1631 cm-1, characteristic of β-sheet structure, 
was observed for PO6C fibers, suggesting that β-sheets help stabilize and promote fiber 
formation (Figure 5.35).110-111 
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Figure 5.35. FTIR spectra of PO18C vesicles (red line) and PO6C fibers (blue line) assembled in 50 mM CaCl2. 
 
 Multiple interdependent factors influence the morphology of PO18C and PO6C 
assemblies, including salt concentration, oligonucleotide length, and the presence or absence of 
β-sheet structure. For PO18C, with a long oligonucleotide, fibers are not favored at low salt 
concentrations, presumably due to interstrand repulsive interactions between the phosphate 
backbones. However, at sufficiently high salt concentrations (e.g., 300 mM CaCl2), enhanced 
charge-screening enables tighter packing of the oligonucleotides, allowing for the parallel 
alignment of PO18Cs into β-sheet networks that facilitate fiber formation (Figure 5.33a).  For 
PO6C, with a much shorter oligonucleotide, tight parallel packing of the POCs can occur at lower 
salt concentrations, which enables β-sheet formation and the assembly of fibers. As the salt 
concentration is lowered, a threshold can be reached at which charge repulsions between the 
phosphate backbones becomes significant enough to favor sphere formation (Figure 5.33b). 
 Our data and observations point to the possibility of morphology prediction based on the 
‘charge ratio,’ defined as the ratio of the total number of positive charges from the Ca+2 in 
solution to the total number of negative charges on the POC (Figure 5.36a). As the charge ratio 
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increases, so does the propensity for fiber formation; as it decreases, the propensity for forming 
spheres increases (Figure 5.36b). Based on these trends, we explored the possibility of changing 
POC assembly morphology by changing the charge ratio of the assembly solution. PO18C 
vesicles were first assembled in 50 mM CaCl2 (Figure 5.36c); thereafter, a small volume of 
concentrated CaCl2 solution was added to increase the charge ratio of the assembly mixture from 
10 to 67. After one day, fibers were observed (Figure 5.36d). This result confirms our 
hypothesis that altering the charge ratio should induce a morphological change, which can serve 
as a design rule for future exploration of POC-based assembly. 
 
 
Figure 5.36. (a) The charge ratio value is the ratio of positive to negative charges of the assembly solution (N = 
number of oligonucleotide bases; the ‘+2’ results from the azido-functionalized T residue, Figure S5.68, and the 
deprotonated COO- terminus of the peptide. (b) The charge ratio of the assembly solution as a function of CaCl2 
concentration and oligonucleotide length. TEM images of PO18C vesicles (c) before and (d) after conc. CaCl2 
addition. 
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 One of the most powerful aspects of the POC design is the ability to introduce a highly 
specific chemical effector into the system in the form of a complementary oligonucleotide. In 
addition to changes in the rigidity of the oligonucleotide component, such a hybridization would 
also affect the assembly behavior by decreasing the charge ratio. To this end, subjecting a 
mixture of PO18C (500 µM) and the O18-complementary oligonucleotide (500 µM) in 150 mM 
CaCl2 to our assembly conditions clearly revealed defined spherical structures as observed by 
TEM (Figure S5.85c,d). In contrast, the PO18C-alone control only showed ill-defined spherical 
structures or fibers at this salt concentration (Figure S5.72 and Figure S5.85a,b). While the 
enhanced rigidity upon duplex formation cannot be ignored, these preliminary data indicate that 
adjusting the charge ratio is a straightforward way to adjust the POC assembled structure. 
5.3 CONCLUSION 
In conclusion, we demonstrated that POCs are versatile building blocks for the programmable 
assembly of new soft materials. With oligonucleotide-biphenyl-peptide as the first POC 
prototype, assembly morphology can be readily controlled by adjusting the length of the 
oligonucleotide and the ionic strength of the assembly solution. These studies only scratch the 
surface of the rich assembly space and morphology control that can be enabled by designing new 
members of the POC family with variations in peptide sequence, cross linkers, conjugate 
valency, and oligonucleotide structure and sequence. Lastly, the observation that POCs can be 
induced to assemble into multiple structures heralds the prospect of using these building blocks 
to build materials that can undergo morphological changes in response to external conditions or 
stimuli. 
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5.4 EXPERIMENTAL SECTION 
5.4.1 General materials and methods 
All chemicals were purchased from either Aldrich or Fisher and used without further 
purification. N3-C4H8CO-AAAYSSGAPPMPPF (N3-A2PEPAu, Figure S5.69) was purchased 
from ThermoFisher Scientific. Gold nanoparticles were purchased from Ted Pella (#15702-20 
and #15704-20 for 5 and 15 nm particles, respectively).  Peptide oligonucleotide chimeras 
(POCs) were purified using an Agilent 1200 Series reverse-phase high-pressure liquid 
chromatography (HPLC) instrument equipped with an Agilent Zorbax 300SB-C18 column. POCs 
were quantified based on their absorbance at 260 nm and using the total extinction coefficient of 
DNA (195,100 M-1cm-1 and 62,800 M-1cm-1 and PO18C and PO6C, respectively). Spectra were 
collected using an Agilent 8453 UV-Vis spectrometer equipped with deuterium and tungsten 
lamps. Transmission electron microscopy (TEM) samples were prepared by drop-casting 4 µL of 
solution onto a 3-mm-diameter copper grid coated with formvar. After 4 min., the excess 
solution was wicked away and the grid was washed with nanopure H2O (4 µL) and wicked away 
immediately. TEM images were collected with a FEI Morgagni 268 (80 kV) equipped with an 
AMT side mount CCD camera system. AFM samples were prepared by drop-casting 6 µL of 
solution onto freshly cleaved mica or mica functionalized with 3-
aminopropyltriethoxysilane(APTES) and air dried. The samples were washed with 30 µL 
Nanopure H2O and wicked away (repeated once). The samples were allowed to dry overnight. 
AFM images were collected with an Asylum MFP-3D atomic force microscopy using tapping-
mode. Images were obtained using ultra-sharp AFM tips (NanoandMore, SHR-150), with a 0.8 
Hz scanning rate and 512 pixel resolution. Scanning electron microcopy (SEM) samples were 
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prepared by drop-casting 5 µL of solution onto silicon wafers and allowed to dry. The samples 
were then washed with 5 µL nanopure H2O and wicked away and allowed to dry overnight. SEM 
images were collected using a ZEISS Sigma 500 VP SEM. Matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) data were collected 
using an Applied Biosystem Voyager System 6174 MALDI-TOF mass spectrometer (negative 
reflector mode; accelerating voltage: 20kV) with 3-hydroxypicolinic acid (3-HPA) as the 
ionization matrix. Nanopure water (NP H2O, 18 MΩ) was obtained from a Barnstead DiamondTM 
water purification system. All TEM measurements were made using ImageJ software. 
5.4.2 Preparation of O18-N3 and O6-N3 
In a typical procedure, syntheses were carried out from the 3′ direction using controlled pore 
glass (CPG) beads possessing 1 µmol of adenine (Glen Research, dA-CPG #20-2001-10, (1000 
Å, 38 µmol/g)). The CPG beads were placed in a 1 µmol synthesis column and Ultramild 3′-
phosphoramidites (Glen Research, Pac-dA-CE phosphoramidite #10-1601-05, Ac-dC-CE 
phosphoramidite #10-1015-C5, iPr-Pac-dG-CE phosphoramidite #10-1621-05, dT-CE 
phosphoramidite #10-1030-C5) and 5′-Iodo-dT phosphoramidite (Glen Research, #10-1931-90) 
were then added using the standard 1 μmol protocol on an Expedite 8909 synthesizer.  Note, a 
mild Cap A Mix (Glen Research, 5% Phenoxyacetic anhydride in THF, #40-4212-52) was also 
used for synthesis to the lability of the Iodo moiety. At the end of the synthesis, the beads were 
dried overnight and kept in a tightly capped vial at ambient conditions. 
The terminal Iodo groups were substituted for azides using an established procedure.164 
The CPG beads were kept in the columns while a saturated mixture of sodium azide in 
anhydrous dimethylformamide (DMF) was prepared (approximately 30 mg per 1 mL, per 1 
 87 
μmol). Upon pulling up 1 mL of the mixture in a syringe, the column was firmly attached with 
an empty syringe on one end and the one containing the mixture in the other. The mixture was 
slowly passed over the CPG beads several times before either being left at ambient overnight or 
placed in a shaker at 60 °C for one hour.  The beads were then washed thoroughly with DMF and 
acetone before drying with nitrogen. The solid-phase coupling reactions with the organic core 
were performed using these dry CPG beads. 
5.4.3 Attachment of azido-modified oligonucleotide to diacetylene biphenyl organic core 
Dry CPG beads containing azide-modified DNA were placed in an Eppendorf tube.  The 
biphenyl core (200 mM in DMF, 200 equivalents based on the azide-DNA strands on CPG 
beads, assuming a 100% yield in the oligonucleotide synthesis), tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA, 100 mM in DMF, 100 equivalents based on the 
azide-DNA strands on CPGs), CuSO4·5H2O (100 mM in DMF, 100 equivalents based on the 
azide-DNA strands on CPGs), and L-ascorbic acid (100 mM in DMF, 100 equivalents based on 
the azide-DNA strands on CPGs) were also added.  The reaction mixture was then blanketed 
with nitrogen before capping and shook for 7 to 18 hours at 25 °C in an Eppendorf® 
Thermomixer® R (Eppendorf, #022670107) at 1000 rpm. It is important that the CPG beads are 
constantly agitated while mixing and not sitting at the bottom of the tube. 
Once the reaction was complete, the CPG beads were filtered using a one-side fritted 1 
µmol Expedite DNA synthesis column (Glen Research, #20-0021-01), then the beads were 
washed with DMF (5×1 mL) and acetone (5×1 mL) and dried with nitrogen. The beads were 
then placed in 1 mL of AMA (CAUTION:  Only fresh AMA solutions that are not more than two 
weeks old and have been kept in the refrigerator below 0 °C should be used) at 65 °C for 15 
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minutes to cleave the conjugates from the solid supports.  Afterwards, the ammonia and methyl 
amine were removed by passing a stream of nitrogen over the solution.  To the remaining 
material was added ultrapure deionized H2O (affording roughly 1 mL at the end), and the 
resulting solution was filtered through 0.45 μm nylon syringe filter (Acrodisc® 13 mm syringe 
filter #PN 4426T). The filtered solution was purified using reverse-phase HPLC eluting with a 
linear gradient of CH3CN and 0.1 M TEAA (5/95 to 45/55 over 30 min.). 
5.4.4 Attachment of azido-modified peptide  
The POCs were prepared using copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) 80-81 in 
which N3-A2PEPAu (Figure S5.69) was reacted with the azido-modified 18mer and 6mer 
conjugates (Figure S5.68). A representative protocol for PO18C is detailed here (the same 
procedure was used for synthesizing PO6C).  The following stock solutions were prepared: A, 
198.3 mM CuSO4 in NP H2O; B, 37.3 mM THPTA in NP H2O; C, 2 M urea in NP H2O; and D, 
60.6 mM sodium ascorbate in NP H2O. Lyophilized N3-A2PEPAu (125 nmol) was dissolved in 70 
µL of DMF and 50 µL of NP H2O and the solution was transferred to a vial containing N3-BP-
Oligo (100 nmol, Figure S1). To this vial were added a mixture of A and B (1.05 µL A mixed 
with 5.58 µL B), 1.5 µL of C, and 13.8 µL of D. The vial was parafilmed and wrapped in 
aluminum foil, and stirred for at least 4 h at room temperature. DMF/NP H2O (1:1) was added to 
bring the total volume to 500 µL. The resulting solution was desalted using a NAP-5 desalting 
column (GE Healthcare Life Sciences, #17-0853-02). The eluted solution was purified using 
reverse-phase HPLC eluting with a linear gradient of CH3CN and 0.1 M TEAA (5/95 to 45/55 
over 30 min.). 
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5.4.5 POC assembly protocol 
In a 250 µL plastic vial, lyophilized POCs (20 nmol) were dissolved in CaCl2 solution to yield 
the desired concentration. The solutions were sonicated for 2 minutes, and centrifuged briefly. 
The vials were placed in a 1.5 mL centrifuge tube containing water that was pre-heated at 80°C 
in an Eppendorf® Thermomixer® R (Eppendorf, # 022670107), and the POC solutions were 
allowed to incubate for 15 min. at 80°C. After incubation, the temperature setting was lowered 
1°C every 5 min. until the temperature reached 25°C. It is important to note that at 70°C the 
samples were centrifuge very briefly to maintain POC concentration. After cooling to 25°C, the 
POC solutions were removed from the 1.5 mL centrifuge tube and allowed to sit overnight at 
room temperature. TEM samples were prepared after 15 to 20 hrs. 
5.4.6 Preparation of DNA-functionalized gold nanoparticles 
5 and 15 nm gold nanoparticles were functionalized using methods developed previously.165 To 
lyophilized complementary oligonucleotides functionalized with thiol hexyl linker at the 5′ 
(purchased from IDT, 10 OD) was added 200 µL of freshly prepared dithiothreitol (DTT) and 
phosphate buffer (PB) solution (100 mM DTT in 170 mM PB). The solution was allowed to 
react for 1 hr. The cleaved oligonucleotides were purified using a NAP-5 column. The purified 
oligonucleotides (in 1 mL NP H2O) were then added to 10 mL of particles. The particle solution 
was allowed to sit overnight. The next morning, the concentrations of PB and sodium dodecyl 
sulfate (SDS) were brought to 0.01 M and 0.01%, respectively. The oligonucleotide/gold 
nanoparticle solution was allowed to incubate at room temperature for 30 min. The concentration 
of NaCl was increased slowly to 0.5 M (in 6 increments) using 2 M NaCl. After each addition of 
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NaCl, the solution was sonicated for 10 sec. and incubated for 30 min. before the next addition. 
After the salting procedure, excess oligonucleotides were removed via centrifugation (1 hr.; 
16,100 x g for 15 nm particles and 10900 x g for 5 nm particles), and subsequent supernatant 
removal. The remaining pellets were combined and the washing process was repeated twice 
more. The final oligonucleotide/functionalized nanoparticle pellet was suspended in 100 µL of 
NP H2O. The gold nanoparticle concentration was determined via UV-Vis spectroscopy using 
extinction coefficients of 2.4 x 108 L/(mol·cm)165 and 9.696 x 106 L/(mol·cm)5 for 15 and 5 nm 
particles, respectively. The concentrations of these stock solutions of nanoparticles were 4.09 x 
1014 and 2.17 x 1013 particles in 100 µL NP H2O, for the 5 nm and 15 nm stock solutions, 
respectively. 
5.4.7 Addition of DNA-functionalized gold nanoparticles to PO18C vesicles and PO6C 
fibers 
To a solution of PO18C vesicles (30 µL) assembled in 50 mM CaCl2 was added 1 µL of a 25x 
diluted solution of the 15 nm stock solution prepared above. The mixture was mixed and 
vortexed briefly and allowed to sit at room temperature for 1 hr. TEM samples were prepared 
after 15 hrs. 
To a solution of PO6C fibers (30 µL) assembled in 50 mM CaCl2 was added 1 µL of a 
10x diluted solution of the 5 nm stock solution prepared above. The mixture was mixed and 
vortexed briefly and allowed to sit at room temperature for 1 hr. TEM samples were prepared 
after 15 hrs. 
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APPENDIX A 
SUPPORTING INFORMATION FOR CHAPTER 2: “ADJUSTING THE METRICS OF 
1D HELICAL NANOPARTICLE SUPERSTRUCTURES USING MULTIVALENT 
PEPTIDE CONJUGATES” 
 
 
 
 
Figure S2.37. Plasmonic circular dichroism signal as a function of helical pitch, calculated according to reported 
methods.61 
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Figure S2.38. Chemical structure of N3-PEPAu 
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Figure S2.39. Scheme detailing the construction of the monovalent, divalent, and trivalent alkyne-modified aliphatic 
substrates. Briefly, the experimental details include: a) EDC-mediated NHS activation of the carboxylic acid, b) 
amide bond formation, and c) propargylation under basic conditions. 
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Figure S2.40. MALDI-TOF mass spectra of purified monovalent and divalent peptide conjugates: (a) C12-(PEPAu)1, 
m/z = 1649.5 (M + Na+); (b) C14-(PEPAu)1, m/z = 1677.3 (M + Na+); (c) C16-(PEPAu)1, m/z = 1693.2 (M + Na+); (d) 
C18-(PEPAu)1, m/z = 1733.1 (M + Na+), m/z = 1748.9 (M + K+); (e) C12-(PEPAu)2, m/z = 3063.4 (M + Na+); (f) C14-
(PEPAu)2, m/z = 3092.2 (M + Na+); (g) C16-(PEPAu)2, m/z = 3119.0 (M + Na+); (h) C18-(PEPAu)2, m/z = 3147.8 (M + 
Na+). 
 
 
 95 
 
 
Figure S2.41. LCMS spectra of purified trivalent peptide conjugates: (a) C12-(PEPAu)3, m/z = 1484 (m/3), m/z = 
1113 (m/4), m/z = 890 (m/5); (b) C14-(PEPAu)3, m/z = 1494 (m/3), m/z = 1120 (m/4); (c) C16-(PEPAu)3, m/z = 1505 
(m/3), m/z = 1129 (m/4); (d) C18-(PEPAu)3, m/z = 1513 (m/3), m/z = 1134 (m/4), m/z = 907 (m/5). 
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Figure S2.42. ATR-FTIR spectra of (a) C18-(PEPAu)1 and (b) its corresponding negatively stained TEM image of the 
soft assembly. ATR-FTIR spectra of (c) C18-(PEPAu)2 and (d) its corresponding negatively stained TEM image of the 
soft assembly. ATR-FTIR spectra of (e) C18-(PEPAu)3 and (f) its corresponding negatively stained TEM image of the 
soft assembly (scale bar = 100 nm) 
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Figure S2.43. Pitch measurements of selected fibers from negatively stained TEM images of (a) C12-(PEPAu)1; (b) 
C14-(PEPAu)1; (c) C16-(PEPAu)1; and (d) C18-(PEPAu)1 (scale bar = 100 nm). Note: in general, the measurements from 
TEM confirm the trend determined from the AFM data. However, the TEM pitch measurements can vary widely 
between different fibers, as is clear for the C12-(PEPAu)1 assemblies. 
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Figure S2.44. (a) AFM images of C12-(PEPAu)1 assemblies and (b) corresponding height traces. The pitch length 
was calculated by averaging the distances between every other peak in the height traces. Average pitch is 186 ± 13 
nm based on 18 counts. 
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Figure S2.45. (a) AFM image of C14-(PEPAu)1 assemblies and (b) corresponding height traces. The pitch length was 
calculated by averaging the distances between every other peak in the height traces. Average pitch is 196 ± 11 nm 
based on 20 counts. It is clear that some fibers intertwine, but the pitch measurements were only made on single 
fibers. 
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Figure S2.46. (a) AFM image of C16-(PEPAu)1 assemblies and (b) corresponding height traces. The pitch length was 
calculated by averaging the distances between every other peak in the height traces. Average pitch is 214 ± 7 nm 
based on 10 counts. It is clear that some fibers intertwine, but the pitch measurements were only made on single 
fibers. 
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Figure S2.47. (a) AFM image of C18-(PEPAu)1 assemblies and (b) corresponding height traces. The pitch length was 
calculated by averaging the distances between every other peak in the height traces. Average pitch is 228 ± 30 nm 
based on 8 counts. It is clear that some fibers intertwine, but the pitch measurements were only made on single 
fibers. 
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Figure S2.48. AFM image of C14-(PEPAu)2 assemblies. Only spherical assemblies/aggregates were observed. 
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Figure S2.49. (a) AFM image of C16-(PEPAu)2 assemblies and (b) corresponding height traces. The pitch length was 
calculated by averaging the distances between every other peak in the height traces. Average pitch is 178 ± 20 nm 
based on 20 counts. It is clear that some fibers intertwine, but the pitch measurements were only made on single 
fibers. 
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Figure S2.50. (a) AFM image of C18-(PEPAu)2 assemblies and (b) corresponding height traces. The pitch length was 
calculated by averaging the distances between every other peak in the height traces. Average pitch is 184 ± 15 nm 
based on 9 counts. It is clear that some fibers intertwine, but the pitch measurements were only made on single 
fibers. 
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Figure S2.51. Molecular structure of the (a) mono- and (b) divalent peptide conjugates used for the QCM 
experiments. MALDI-TOF mass spectra of (c) monovalent peptide conjugate, m/z = 1424 (M + Na+), m/z = 1440.0 
(M + K+) and (d) divalent peptide conjugate, m/z = 2866.1 (M + Na+). 
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Figure S2.52. (a) TEM image showing the interchain distances (scale bar = 50 nm). Interchain distances of (b) C14-
(PEPAu)1: 5.9 ± 1.2 nm based on 65 counts; (c) C16-(PEPAu)1: 5.6 ± 1.2 nm based on 65 counts; (d) C16-(PEPAu)2: 4.6 
± 1.2 nm based on 55 counts; (e) C18-(PEPAu)2: 5.0 ± 1.4 nm based on 35 counts. 
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Figure S2.53. Possible locations for particle association to fibers: (a) fiber faces or (b) fiber edges. 
 
 
 
 
 
 
Figure S2.54. TEM images indicating helical segments of assemblies constructed from (a,b) C14-(PEPAu)1 and (c) 
C16-(PEPAu)2 (scale bar = 100 nm). The red arrows indicate points of helicity. 
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Synthesis and Characterization of Alkyne-Modified Aliphatic Substrates 
 
Myristic N-hydroxyl-succinimide ester 
 
Myristic acid (268.5 mg, 1.18 mmol) was dissolved in 10 mL of dry dimethylformamide (DMF). 
N-hydroxysuccinimide (270.0 mg, 2.35 mmol) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (451.0 mg, 2.35 mmol) were added to the solution.  While 
stirring, N,N-diisopropylethylamine (408 µl, 2.35 mmol) was then added, and the reaction 
mixture was stirred at room temperature for 15 hours.  After 15 hours, a white precipitate was 
observed.  Acidified NP H2O (pH ~4)  was added to the mixture and the white solid was 
collected by vacuum filtration. The collected solid was dried in vacuo.  Yield: 304.1 mg, 79 %. 
1H NMR (300 MHz, CDCl3) δ 2.81 (s, 4H), 2.58 (t, 2H), 1.72 (m, 2H), 1.41 – 1.32 (m, 2H), 1.31 
– 1.20 (m, 18H), 0.86 (t, 3H). 
 
 
Stearic N-hydroxyl-succinimide ester 
     
Stearic acid (479.0 mg, 1.68 mmol) was dissolved in 10 mL of dry DMF.  N-
hydroxysuccinimide (339.1 mg, 2.95 mmol) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (565.9 mg, 2.95 mmol) were added to the solution.  While 
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stirring, N,N-diisopropylethylamine (512 µl, 2.95 mmol) was then added, and the reaction 
mixture was stirred at room temperature for 15 hours.  After 15 hours, a white precipitate was 
observed.  Acidified NP H2O (pH~4) was added to the mixture and the white solid was collected 
by vacuum filtration. The collected solid was dried in vacuo.  Yield: 530.2 mg,  83 %. 1H NMR 
(300 MHz, CDCl3) δ 2.83 (s, 4H), 2.60 (t, 2H), 1.74 (m, 2H), 1.43 – 1.32 (m, 2H), 1.32 – 1.20 
(m, 26H), 0.88 (t, 3H). 
 
 
 (m12-OH, C14H29NO2) 
Lauric N-hydroxyl-succinimide ester (183.8 mg, 0.62 mmol) was dissolved in 4 mL of 
dichloromethane (DCM). Ethanolamine (74.4 µL, 1.24 mmol) was added to the solution. While 
stirring, triethylamine (172 µL, 1.24 mmol) was then added, and the reaction mixture was stirred 
at room temperature for 15 hours. The reaction mixture was transferred to a separatory funnel 
and washed with NP H2O (1x) and brine (2x). The organic layer was collected and dried over 
MgSO4. The mixture was filtered and the DCM was evaporated under air flow to yield product 
which was dried in vacuo.  Yield: 104.9 mg, 70 %. 1H NMR (300 MHz, CDCl3) δ 7.73 (t, 1H), 
4.62 (t, 1H), 3.36 (q, 2H), 3.08 (q, 2H), 2.04 (t, 2H), 1.51 – 1.40 (m, 2H), 1.31 – 1.15 (m, 16H), 
0.85 (t, 3H). 
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 (m14-OH, C16H33NO2) 
Myristic N-hydroxyl-succinimide ester (146.3 mg, 0.45 mmol) was dissolved in 8 mL of dry 
DMF. Ethanolamine (54.0 µL, 0.90 mmol) was added to the solution. While stirring, 
triethylamine (93.1 µL, 0.67 mmol) was then added, and the reaction mixture was stirred at room 
temperature for 15 hours. After reaction, a white precipitate was observed. The product was 
precipitated with NP H2O, recovered by vacuum filtration, and then dried in vacuo.  Yield: 70.1 
mg, 57 %. 1H NMR (300 MHz, DMSO) δ 7.73 (t, 1H), 4.61 (t, 1H), 3.36 (q, 2H), 3.08 (q, 2H), 
2.04 (t, 2H), 1.51 – 1.40 (m, 2H), 1.30 – 1.17 (m, 20H), 0.85 (t, 3H). 
 
 
 (m16-OH, C18H37NO2) 
Palmitic N-hydroxyl-succinimide ester (144.5 mg, 0.41 mmol) was dissolved in 10 mL of dry 
DMF. Ethanolamine (49.1 µL, 0.82 mmol) was added to the solution. While stirring, 
triethylamine (84.7 µL, 0.61 mmol) was then added, and the reaction mixture was stirred at room 
temperature for 15 hours. The product was precipitated with NP H2O, recovered by vacuum 
filtration, and then dried in vacuo.  Yield: 90.5 mg, 74 %. 1H NMR (300 MHz, DMSO) δ 7.72 (t, 
1H), 4.61 (t, 1H), 3.36 (q, 2H), 3.08 (q, 2H), 2.04 (t, 2H), 1.51 – 1.40 (m, 2H), 1.30 – 1.17 (m, 
24H), 0.85 (t, 3H). 
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 (m18-OH, C20H41NO2) 
Stearic N-hydroxyl-succinimide ester (175.4, 0.46 mmol) was dissolved in 10 mL of dry DMF. 
Ethanolamine (55.3 µL, 0.92 mmol) was added to the solution. While stirring, triethylamine 
(95.2 µL) was then added, and the reaction mixture was stirred at room temperature for 15 hours. 
After reaction, a white precipitate was observed.  The product was precipitated with NP H2O, 
recovered by vacuum filtration, and then dried in vacuo. Yield: 111.9 mg, 74 %. 1H NMR (300 
MHz, DMSO) δ 7.73 (t, 1H), 4.62 (t, 1H), 3.36 (q, 2H), 3.08 (q, 2H), 2.04 (t, 2H), 1.51 – 1.40 
(m, 2H), 1.30 – 1.15 (m, 28H), 0.85 (t, 3H). 
 
 
  (d12-OH, C15H31NO2) 
Lauric N-hydroxyl-succinimide ester (186.4 mg, 0.63 mmol) was dissolved in 5 mL of dry DMF. 
2-amino-1,3-propanediol (~20 mg, ~1.2 mmol) was combined with 1 mL of dry DMF and then 
added to the solution. While stirring, triethylamine (132 µL, 0.94 mmol) was then added, and the 
reaction mixture was stirred at room temperature for 15 hours. After reaction, a white precipitate 
was observed. The product was precipitated with acidified NP H2O (pH ~4). The gel-like 
precipitate was recovered by vacuum filtration and then dried in vacuo. Yield: 149.0 mg, 86 %. 
1H NMR (300 MHz, DMSO) δ 7.41 (d, 1H), 4.55 (t, 2H), 3.73 – 3.62 (m, 1H), 3.37 (t, 4H), 2.06 
(t, 2H), 1.52 – 1.40 (m, 2H), 1.32 – 1.13 (m, 16H), 0.85 (t, 3H). 
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  (d14-OH, C17H35NO2) 
Myristic N-hydroxyl-succinimide ester (135.3 mg, 0.42 mmol) was dissolved in 4 mL of dry 
DMF. 2-amino-1,3-propanediol (~90 mg, ~1 mmol) was combined with 1 mL of dry DMF and 
then added to the solution. While stirring, triethylamine (86.3 µL, 0.62 mmol) was then added, 
and the reaction mixture was stirred at room temperature for 15 hours. After reaction, a white 
precipitate was observed. The product was precipitated with acidified NP H2O (pH ~4). The gel-
like precipitate was recovered by vacuum filtration and then dried in vacuo.  Yield: 95.7 mg, 76 
%. 1H NMR (300 MHz, DMSO) δ 7.40 (d, 1H), 4.54 (t, 2H), 3.72 – 3.64 (m, 1H), 3.37 (t, 4H), 
2.06 (t, 2H), 1.52 – 1.40 (m, 2H), 1.39 – 1.14 (m, 20H), 0.85 (t, 3H). 
 
 
   (d16-OH, C19H39NO2) 
Palmitic N-hydroxyl-succinimide ester  (133.4, 0.38 mmol) was dissolved in 7 mL of dry DMF. 
2-amino-1,3-propanediol (~83 mg, ~0.8 mmol) was combined with 1 mL of dry DMF. While 
stirring, triethylamine (78.9 µL, 0.57 mmol) was then added, and the reaction mixture was stirred 
at room temperature for 15 hours. After reaction, a white precipitate was observed. The product 
was precipitated with acidified NP H2O (pH ~4). The white solid was recovered by vacuum 
filtration and then dried in vacuo. Yield: 63.5 mg, 51 %. 1H NMR (300 MHz, DMSO) δ 7.41 (d, 
1H), 4.55 (s, 2H), 3.71 – 3.63 (m, 1H), 3.37 (t, 4H), 2.05 (t, 2H), 1.50 – 1.40 (m, 2H), 1.31 – 1.17 
(m, 24H), 0.85 (t, 3H). 
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 (d18-OH, C21H43NO2) 
Stearic N-hydroxyl-succinimide ester (189.5 mg, 0.50 mmol) was dissolved in 13 mL of dry 
DMF. The solution remained a cloudy white due to incomplete dissolution. 2-amino-1,3-
propanediol (~106 mg, ≥ 1 mmol) was combined with 1 mL of dry DMF. While stirring, 
triethylamine (104 µL, 0.75 mmol) was then added, and the reaction mixture was stirred at room 
temperature for 15 hours. After reaction, a white precipitate was observed. The product was 
precipitated with acidified NP H2O (pH ~4). The white solid was recovered by vacuum filtration 
and then dried in vacuo. Yield: 125.2 mg, 70 %. 1H NMR (300 MHz, DMSO) δ 7.41 (d, 1H), 
4.55 (s, 2H), 3.72 – 3.65 (m, 1H), 3.37 (t, 4H), 2.05 (t, 2H), 1.50 – 1.40 (m, 2H), 1.30 – 1.17 (m, 
28H), 0.85 (t, 3H). 
 
 
 (t12-OH, C16H33NO2) 
Lauric N-hydroxyl-succinimide ester (198.7 mg, 0.67 mmol) was dissolved in 10 mL of dry 
DMF. Tris(hydroxymethyl)aminomethane (202.3 mg, 1.67 mmol) was then added to the 
solution. The resulting solution was sonicated to ensure complete dissolution. While stirring, 
triethylamine  (186 µL, 1.34 mmol) was then added, and the reaction mixture was stirred at room 
temperature for 15 hours. After reaction, ~5 mL of NP H2O and ~3-4 mL of 1 M HCl were added 
to the product solution, bringing the pH to ~3-4. White precipitate was observed. The cloudy 
solution was then transferred to a 15 mL centrifuge tube. The solid product was collected via 
centrifugation; the supernatant was discarded. The product was rinsed with additional acidified 
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NP H2O (pH ~4) and collected via centrifugation. After decanting the supernatant, the white 
solid was collected via vacuum filtration and then dried in vacuo. Yield: 123.9 mg, 61 %.  1H 
NMR (300 MHz, DMSO) δ 7.08 (s, 1H), 4.75 (t, 3H), 3.51 (d, 6H), 2.11 (t, 2H), 1.50 – 1.40 (m, 
2H), 1.30 – 1.15 (m, 16H), 0.85 (t, 3H). 
 
 
 (t14-OH, C18H37NO2) 
Myristic N-hydroxyl-succinimide ester (159.4 mg, 0.49 mmol) was dissolved in 10 mL of dry 
DMF. Tris(hydroxymethyl)aminomethane (119.0 mg, 0.98 mmol) was then added to the 
solution. The resulting solution was sonicated to ensure complete dissolution. While stirring, 
triethylamine (102 µL, 0.73 mmol) was then added, and the reaction mixture was stirred at room 
temperature for 15 hours. After reaction, ~5 mL of NP H2O and ~3-4 mL of 1 M HCl were added 
to the product solution, bringing the pH to ~3-4. White precipitate was observed. The cloudy 
solution was then transferred to a 15 mL centrifuge tube. The solid product was collected via 
centrifugation; the supernatant was discarded. The product was rinsed with additional acidified 
NP H2O (pH ~4) and collected via centrifugation. After decanting the supernatant, the white 
solid was collected via vacuum filtration and then dried in vacuo. Yield: 113.9 mg, 70 %.  1H 
NMR (300 MHz, DMSO) δ 7.07 (s, 1H), 4.75 (t, 3H), 3.51 (d, 6H), 2.12 (t, 2H), 1.50 – 1.40 (m, 
2H), 1.30 – 1.15 (m, 20H), 0.85 (t, 3H). 
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  (t16-OH, C20H41NO2) 
Palmitic N-hydroxyl-succinimide ester (175.2 mg, 0.50 mmol) was dissolved in 10 mL of dry 
DMF.  Tris(hydroxymethyl)aminomethane (120.1 mg, 0.99 mmol). The resulting solution was 
sonicated to ensure complete dissolution. While stirring, triethylamine  (103 µL, 0.74 mmol) was 
then added, and the reaction mixture was stirred at room temperature for 15 hours. After 
reaction, 1.5 mL of 1 M HCl followed by 25 mL H2O were added to the reaction, and a white 
precipitate was observed.  The cloudy solution was then transferred to a 15 mL centrifuge tube. 
The solid product was collected via centrifugation; the supernatant was discarded. The product 
was rinsed with NP H2O and collected via centrifugation. After decanting the supernatant, the 
white solid was collected via vacuum filtration and then dried in vacuo. Yield: 61.9 mg, 35 %. 
1H NMR (300 MHz, DMSO) δ 7.07 (s, 1H), 4.74 (t, 3H), 3.51 (d, 6H), 2.12 (t, 2H), 1.50 – 1.40 
(m, 2H), 1.30 – 1.15 (m, 24H), 0.85 (t, 3H). 
 
 
 (t18-OH, C22H45NO2) 
Stearic N-hydroxyl-succinimide ester (153.7 mg, 0.40 mmol) was dissolved in 10 mL of dry 
DMF. Tris(hydroxymethyl)aminomethane (97.6 mg, 0.80 mmol) was then added to the solution. 
The resulting solution was sonicated to ensure complete dissolution. While stirring, triethylamine 
(84.6 µL, 1.34 mmol) was then added, and the reaction mixture was stirred at room temperature 
for 15 hours. After reaction, NP H2O was added to the flask and a white/clear gel was observed.  
The cloudy solution was then transferred to a 15 mL centrifuge tube and centrifuged. The solid 
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product was collected via centrifugation; the supernatant was discarded. The product was rinsed 
with NP H2O and collected via centrifugation. After decanting the supernatant, the white solid 
was collected via vacuum filtration and then dried in vacuo. Yield: 74.5 mg, 48 %. 1H NMR (300 
MHz, DMSO) δ 7.08 (s, 1H), 4.75 (t, 3H), 3.51 (d, 6H), 2.11 (t, 2H), 1.50 – 1.40 (m, 2H), 1.30 – 
1.17 (m, 28H), 0.85 (t, 3H). 
 
 
  (m12-CC, C17H31NO2) 
m12-OH (119.2 mg, 0.49 mmol) was dissolved in 6 mL of dry DMF. An 80% by mass solution 
of propargyl bromide in toluene (163 µL, 1.47 mmol) was added to the solution. The reaction 
flask was placed in an ice bath, and after cooling, 1 pellet of KOH, ground into a fine powder, 
was added over 5 min. The reaction flask was placed under argon, removed from the ice bath, 
warmed to room temperature, and stirred at room temperature for 2 days.  After 2 days, the 
solvent was evaporated under reduced pressure, and the resulting product was extracted with 
DCM and washed with brine (3x) and H2O (1x). The organic layer was collected and dried over 
MgSO4. The MgSO4 was removed by filtration and the solvent was removed via rotary 
evaporation. Any remaining DMF was removed in vacuo while heating at 50°C. The resulting 
crude product was purified by column chromatography on silica gel (230-400 Å mesh, 75% ethyl 
acetate in hexanes; Rf = 0.55). Yield: 69.9 mg, 51 %. 1H NMR (300 MHz, DMSO) δ 7.86 (t, 
1H), 4.12 (d, 2H), 3.45 – 3.40 (t, t, 3H), 3.19 (q, 2H), 2.04 (t, 2H), 1.52 – 1.39 (m, 2H), 1.32 – 
1.13 (m, 16H), 0.86 (t, 3H). 
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 (m14-CC, C19H35NO2) 
m14-OH (68.6 mg, 0.25 mmol) was dissolved in 7 mL of dry DMF. An 80% by mass solution of 
propargyl bromide in toluene (70.7 µL; 0.63 mmol) was added to the solution. The reaction flask 
was placed in an ice bath, and after cooling, 1 pellet of KOH, ground into a fine powder, was 
added over 5 min. The reaction flask was placed under argon, removed from the ice bath, 
warmed to room temperature, and stirred at room temperature for 2 days. After 2 days, the 
solvent was evaporated under reduced pressure, and the resulting product was extracted with 
DCM and washed with brine (3x) and H2O (1x). The organic layer was collected and dried over 
MgSO4.  The MgSO4 was removed by filtration, the solvent was removed via rotary evaporation, 
and the crude product was dried in vacuo. The resulting crude product was purified by column 
chromatography on silica gel (230-400 Å mesh, 50% ethyl acetate in hexanes; Rf = 0.45). Yield: 
37.8 mg, 49 %.  1H NMR (300 MHz, DMSO) δ 7.83 (t, 1H), 4.12 (d, 2H), 3.45 – 3.40 (t, t, 3H), 
3.19 (q, 2H), 2.04 (t, 2H), 1.50 – 1.39 (m, 2H), 1.30 – 1.15 (m, 20H), 0.85 (t, 3H). 
 
 
  (m16-CC, C21H39NO2) 
m16-OH (79.9 mg, 0.27 mmol) was dissolved in 4 mL of dry DMF and 2 mL of DCM. An 80% 
by mass solution of propargyl bromide in toluene (74.6 µL, 0.67 mmol) was added to the 
solution.  The reaction flask was placed in an ice bath, and after cooling, 1 pellet of KOH, 
ground into a fine powder, was added over 5 min. The reaction flask was placed under argon, 
removed from the ice bath, warmed to room temperature, and stirred at room temperature for 2 
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days.  After 2 days, the solvent was evaporated under reduced pressure, and the resulting product 
was extracted with DCM and washed with brine (3x) and H2O (1x). The organic layer was 
collected and dried over MgSO4. The MgSO4 was removed by filtration, the solvent was 
removed via rotary evaporation, and the crude product was dried in vacuo.  The resulting crude 
product was purified by column chromatography on silica gel (230-400 Å mesh, 50% ethyl 
acetate in hexanes; Rf = 0.5). Yield: 40.1 mg, 44 %. 1H NMR (300 MHz, DMSO) δ 7.83 (t, 1H), 
4.12 (d, 2H), 3.45 – 3.40 (t, t, 3H), 3.19 (q, 2H), 2.04 (t, 2H), 1.50 – 1.39 (m, 2H), 1.30 – 1.15 
(m, 24H), 0.85 (t, 3H). 
 
 
  (m18-CC, C23H43NO2) 
m18-OH (101.8 mg, 0.31 mmol) was dissolved in 5 mL of dry DMF and 7 mL of dry THF, 
resulting in a slightly cloudy solution. An 80% by mass solution of propargyl bromide in toluene 
(104 µL, 0.93 mmol) was added to the solution.  The reaction flask was placed in an ice bath, 
and after cooling, 1 pellet of KOH, ground into a fine powder, were added over 5 min. The 
reaction flask was placed under argon, removed from the ice bath, warmed to room temperature, 
and stirred at room temperature for 2 days.  After 2 days, the solvent was evaporated under 
reduced pressure, and the resulting product was extracted with DCM and washed with brine (3x) 
and H2O (1x). The organic layer was collected and dried over MgSO4. The MgSO4 was removed 
by filtration, the solvent was removed via rotary evaporation, and the crude product was dried in 
vacuo.  The resulting crude product was purified by column chromatography on silica gel (230-
400 Å mesh, 50% ethyl acetate in hexanes; Rf = 0.5). Yield: 43.0 mg, 38 %. 1H NMR (300 MHz, 
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DMSO) δ 7.83 (t, 1H), 4.12 (d, 2H), 3.45 – 3.39 (t, t, 3H), 3.19 (q, 2H), 2.04 (t, 2H), 1.50 – 1.39 
(m, 2H), 1.30 – 1.15 (m, 28H), 0.85 (t, 3H). 
 
 
  (d12-CC, C21H35NO2) 
d12-OH (68.5 mg, 0.25 mmol) was dissolved in 3 mL of dry DMF. An 80% by mass solution of 
propargyl bromide in toluene (167 µL, 1.50 mmol) was added to the solution.  The reaction flask 
was placed in an ice bath, and after cooling, 1-1.5 pellets of KOH, ground into a fine powder, 
were added over 5 min. The reaction flask was placed under argon, removed from the ice bath, 
warmed to room temperature, and stirred at room temperature for 2 days.  After 2 days, the 
solvent was evaporated under reduced pressure, and the resulting product was extracted with 
DCM and washed with brine (3x) and H2O (1x). The organic layer was collected and dried over 
MgSO4. The MgSO4 was removed by filtration, the solvent was removed via rotary evaporation, 
and the crude product was dried in vacuo.  The resulting crude product was purified by column 
chromatography on silica gel (230-400 Å mesh, 50% ethyl acetate in hexanes; Rf = 0.5). Yield: 
38.5 mg, 44 %. 1H NMR (300 MHz, DMSO) δ 7.75 (d, 1H), 4.12 (d, 4H), 4.07 – 3.97 (m, 1H) 
3.47 – 3.38 (t, d, 6H), 2.06 (t, 2H), 1.52 – 1.40 (m, 2H), 1.35 – 1.13 (m, 16H), 0.85 (t, 3H). 
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  (d14-CC, C23H39NO2) 
d14-OH (88.5 mg, 0.29 mmol) was dissolved in 4 mL of dry DMF. An 80% by mass solution of 
propargyl bromide in toluene (129 µL, 1.17 mmol) was added to the solution.  The reaction flask 
was placed in an ice bath, and after cooling, 1-1.5 pellets of KOH, ground into a fine powder, 
were added over 5 min. The reaction flask was placed under argon, removed from the ice bath, 
warmed to room temperature, and stirred at room temperature for 2 days.  After 2 days, the 
solvent was evaporated under reduced pressure, and the resulting product was extracted with 
DCM and washed with brine (3x) and H2O (1x). The organic layer was collected and dried over 
MgSO4. The MgSO4 was removed by filtration, the solvent was removed via rotary evaporation, 
and the crude product was dried in vacuo.  The resulting crude product was purified by column 
chromatography on silica gel (230-400 Å mesh, 33% ethyl acetate in hexanes; Rf = 0.3). Yield: 
44.2 mg, 40 %. 1H NMR (300 MHz, DMSO) δ 7.74 (d, 1H), 4.13 (d, 4H), 4.07 – 3.97 (m, 1H), 
3.47 – 3.38 (t, d, 6H), 2.06 (t, 2H), 1.50 – 1.40 (m, 2H), 1.31 – 1.16 (m, 20H), 0.85 (t, 3H). 
 
 
 (d16-CC, C25H43NO2) 
d16-OH (62.8 mg, 0.15 mmol) was dissolved in 8 mL of dry DMF. An 80% by mass solution of 
propargyl bromide in toluene (127 µL, 1.14 mmol) was added to the solution.  The reaction flask 
was placed in an ice bath, and after cooling, 1-1.5 pellets of KOH, ground into a fine powder, 
were added over 5 min. The reaction flask was placed under argon, removed from the ice bath, 
 121 
warmed to room temperature, and stirred at room temperature for 2 days.  After 2 days, the 
solvent was evaporated under reduced pressure, and the resulting product was extracted with 
DCM and washed with brine (3x) and H2O (1x). The organic layer was collected and dried over 
MgSO4. The MgSO4 was removed by filtration, the solvent was removed via rotary evaporation, 
and the crude product was dried in vacuo. The resulting crude product was purified by column 
chromatography on silica gel (230-400 Å mesh, 33% ethyl acetate in hexanes; Rf = 0.35). Yield: 
31.0 mg, 51 %. 1H NMR (300 MHz, DMSO) δ 7.73 (d, 1H), 4.12 (d, 4H), 4.06 – 3.96 (m, 1H), 
3.44 – 3.39 (t, d, 6H), 2.06 (t, 2H), 1.50 – 1.39 (m, 2H), 1.35 – 1.13 (m, 24H), 0.85 (t, 3H). 
 
 
  (d18-CC, C27H47NO2) 
d18-OH (44.2 mg, 0.12 mmol) was dissolved in 2 mL of dry DMF and 1.5 mL of dry THF. An 
80% by mass solution of propargyl bromide in toluene (110 µL, 0.99 mmol) was added to the 
solution. The reaction flask was placed in an ice bath, and after cooling, 1-1.5 pellets of KOH, 
ground into a fine powder, were added over 5 min. The reaction flask was placed under argon, 
removed from the ice bath, warmed to room temperature, and stirred at room temperature for 2 
days.  After 2 days, the solvent was evaporated under reduced pressure, and the resulting product 
was extracted with DCM and washed with brine (3x) and H2O (1x). The organic layer was 
collected and dried over MgSO4. The MgSO4 was removed by filtration, the solvent was 
removed via rotary evaporation, and the crude product was dried in vacuo.  The resulting crude 
product was purified by column chromatography on silica gel (230-400 Å mesh, 33% ethyl 
acetate in hexanes; Rf = 0.45). Yield: 22.1 mg, 42 %. 1H NMR (300 MHz, DMSO) δ 7.73 (d, 
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1H), 4.12 (d, 4H), 4.08 – 3.98 (m, 1H), 3.45 – 3.39 (t, d, 6H), 2.06 (t, 2H), 1.50 – 1.39 (m, 2H), 
1.36 – 1.17 (m, 28H), 0.85 (t, 3H). 
 
 
  (t12-CC, C25H39NO2) 
t12-OH (144.5 mg, 0.48 mmol) was dissolved in 6 mL of dry DMF. An 80% by mass solution of 
propargyl bromide in toluene (377 µL, 3.40 mmol) was added to the solution.  The reaction flask 
was placed in an ice bath, and after cooling, 2 pellets of KOH, ground into a fine powder, were 
added over 5 min. The reaction flask was placed under argon, removed from the ice bath, 
warmed to room temperature, and stirred at room temperature for 2 days.  After 2 days, the 
solvent was evaporated under reduced pressure, and the resulting product was extracted with 
DCM and washed with brine (3x) and H2O (1x). The organic layer was collected and dried over 
MgSO4. The MgSO4 was removed by filtration, the solvent was removed via rotary evaporation, 
and the crude product was dried in vacuo; any remaining DMF was removed in vacuo while 
heating at 50°C. The resulting crude product was purified by column chromatography on silica 
gel (230-400 Å mesh, 33% ethyl acetate in hexanes; Rf = 0.6). Yield: 135.4 mg, 67 %. 1H NMR 
(300 MHz, DMSO) δ 7.15 (s, 1H), 4.11 (d, 6H), 3.64 (s, 6H), 3.41 (t, 3H), 2.05 (t, 2H), 1.50 – 
1.37 (m, 2H), 1.30 – 1.15 (m, 16H), 0.85 (t, 3H). 
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  (t14-CC, C27H43NO2) 
t14-OH (85.0 mg, 0.26 mmol) was dissolved in 5 mL of dry DMF. An 80% by mass solution of 
propargyl bromide in toluene (172 µL, 1.54 mmol) was added to the solution. The reaction flask 
was placed in an ice bath, and after cooling, 2 pellets of KOH, ground into a fine powder, were 
added over 5 min. The reaction flask was placed under argon, removed from the ice bath, 
warmed to room temperature, and stirred at room temperature for 2 days.  After 2 days, the 
solvent was evaporated under reduced pressure, and the resulting product was extracted with 
DCM and washed with brine (3x) and H2O (1x). The organic layer was collected and dried over 
MgSO4. The MgSO4 was removed by filtration, the solvent was removed via rotary evaporation, 
and the crude product was dried in vacuo.  The resulting crude product was purified by column 
chromatography on silica gel (230-400 Å mesh, 30% ethyl acetate in hexanes; Rf = 0.5). Yield: 
63.7 mg, 55 %.  1H NMR (300 MHz, DMSO) δ 7.14 (s, 1H), 4.11 (d, 6H), 3.64 (s, 6H), 3.40 (t, 
3H), 2.05 (t, 2H), 1.50 – 1.38 (m, 2H), 1.30 – 1.15 (m, 20H), 0.85 (t, 3H). 
 
 
   (t16-CC, C29H47NO2) 
t16-OH (61.9 mg; 0.17 mmol) was dissolved in 4 mL of dry DMF. An 80% by mass solution of 
propargyl bromide in toluene (115 µL, 1.03 mmol) was added to the solution. The reaction flask 
was placed in an ice bath, and after cooling, 2 pellets of KOH, ground into a fine powder, were 
added over 5 min. The reaction flask was placed under argon, removed from the ice bath, 
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warmed to room temperature, and stirred at room temperature for 2 days.  After 2 days, the 
solvent was evaporated under reduced pressure, and the resulting product was extracted with 
DCM and washed with brine (3x) and H2O (1x). The organic layer was collected and dried over 
MgSO4. The MgSO4 was removed by filtration, the solvent was removed via rotary evaporation, 
and the crude product was dried in vacuo.  The resulting crude product was purified by column 
chromatography on silica gel (230-400 Å mesh, 30% ethyl acetate in hexanes; Rf = 0.5). Yield: 
42.6 mg, 53 %. 1H NMR (300 MHz, DMSO) δ 7.16 (s, 1H), 4.11 (d, 6H), 3.64 (s, 6H), 3.41 (t, 
3H), 2.05 (t, 2H), 1.50 – 1.37 (m, 2H), 1.30 – 1.16 (m, 24H), 0.85 (t, 3H). 
 
 
  (t18-CC, C31H51NO2) 
t18-OH (72.2 mg; 0.19 mmol) was dissolved in 3 mL of dry DMF and 3 mL of dry THF. An 
80% by mass solution of propargyl bromide in toluene (125 µL, 1.12 mmol) was added to the 
solution. The reaction flask was placed in an ice bath, and after cooling, 2 pellets of KOH, 
ground into a fine powder, were added over 5 min. The reaction flask was placed under argon, 
removed from the ice bath, warmed to room temperature, and stirred at room temperature for 2 
days.  After 2 days, the solvent was evaporated under reduced pressure, and the resulting product 
was extracted with DCM and washed with brine (3x) and H2O (1x). The organic layer was 
collected and dried over MgSO4. The MgSO4 was removed by filtration, the solvent was 
removed via rotary evaporation, and the crude product was dried in vacuo.  The resulting crude 
product was purified by column chromatography on silica gel (230-400 Å mesh, 30% ethyl 
acetate in hexanes; Rf = 0.5). Yield: 41.2 mg, 43 %.  1H NMR (300 MHz, DMSO) δ 7.16 (s, 1H), 
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4.10 (d, 6H), 3.64 (s, 6H), 3.41 (t, 3H), 2.04 (t, 2H), 1.49 – 1.38 (m, 2H), 1.30 – 1.15 (m, 28H), 
0.85 (t, 3H). 
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APPENDIX B 
SUPPORTING INFORMATION FOR CHAPTER 3: “PEPTIDE-DIRECTED 
ASSEMBLY OF SINGLE-HELICAL GOLD NANOPARTICLE SUPERSTRUCTURES 
EXHIBITING INTENSE CHIROPTICAL ACTIVITY” 
 
Figure S3.55. Chemical structure of (a) C18-(PEPAu)2 and (b) C18-(PEPAuM-ox)2. 
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Figure S3.56. LCMS spectra of (a) C18-(PEPAu)2, m/z = 1562 (m/2) and C18-(PEPAuM-ox)2, m/z = 1578 (m/2). 
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Figure S3.57. Additional TEM images of the single-helical superstructure at different magnifications. 
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Figure S3.58. The nanoparticle length and widths of the single-helical superstructure were 16.6 ± 3.0 nm and 9.6 ± 
1.9 nm, respectively, after 15 hours of reaction (based on 125 counts each). 
 
 
 
 
Figure S3.59. Negative-stained TEM images of the single helices after (a) 0 min., (b) 30 min., (c) 2 hrs., (d) 5 hrs., 
(e) 8 hrs., and (f) 2 days of reaction at room temperature (scale bars = 50 nm) 
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Figure S3.60. Structural parameters of single helices from cryo-ET: (a) the helical pitch was 102.0 ± 2.5 nm, based 
on 20 counts; (b) rotation angle was 34.3 ± 4.9 degrees, based on 20 counts; and (c) inner diameter was 10.1 ± 0.6 
nm, based on 10 counts. 
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Figure S3.61. (a) CD spectrum of PEPauM-ox capped gold nanoparticles and (b) their corresponding TEM image 
(scale bar = 100 nm). Both single particles and particle aggregates are observed. 
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Figure S3.62. (a) TEM image of helices formed with 10 min. of sonication and 20 min. of incubation prior to 
HAuCl4/TEAA addition. (b) The particle width and lengths were 12.1 ± 3.0 nm and 23.9 ± 3.9 nm, respectively 
(based on 75 counts each). (c) CD spectrum of the optimized single helices exhibit a very strong CD signal. (d) UV-
Vis extinction spectrum, and (e) g-factor graph showing absolute g-factor values up to 0.04. g- factor = Δε/ε, where 
Δε is the molar circular dichroism and ε is the molar extinction. 
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Figure S3.63. (a-d) AFM images of C18-(PEPAuM-ox)2 fibers dispersed on APTES-functionalized mica (scale bars = 
200 nm) and (e) height traces of the labeled segments. 
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Figure S3.64. (a) C18-(PEPAuM-ox)2 in 10 mM HEPES as a function of time. Negative-stained TEM images after (b) 
15 min., (c) 3 hrs., and (d) 72 hrs. are shown (scale bars = 500 nm). Under these conditions, fibers form very slowly, 
and very few fibers are observed at early time points. 
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Figure S3.65. Additional ssNMR results and structural reference. (a) Aliphatic 13C 1D MAS ssNMR spectrum of 
the site-specifically labeled C18-(PEPAuM-ox)2 assemblies (top), with the P10 peaks indicated. Bottom: ssNMR 
spectrum of fibrillar huntingtin exon1-derived peptide httNT Q30P10K2, with 13C-, 15N-labeled Pro P48 (adapted from 
ref. 119). In both cases the labeled Pro is part of a PPII helix that flanks the β-sheet amyloid core. (b) Long-mixing 
500ms PDSD 2D ssNMR spectrum on the labeled C18-(PEPAuM-ox)2 assemblies. Compared to the short-mixing 
spectrum (Figure 3.24b) only new intra-residue P10 peaks are observed, with no contacts between the distinct A1 
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conformers. (c) Compact zipper interfaces mediated by Ser and other small amino acids in amyloid-like crystals of 
peptides SSTSAA and SSTNVG from RNase and IAPP.120 The compact 6 Å inter-sheet distance is indicated. (d) 
Tyr ring stacking in GNNQQNY in-register parallel (IP) β-sheets.166 (e) Amyloid interfaces featuring aromatic 
residues generate wider 9-10 Å inter-sheet distances. Illustrated for Phe in this Class-2 amyloid-like crystal of 
peptide ANFLVH.167  The PDB entries for the four peptide crystal structures are 2ONW, 3DG1, 1YJP, and 5E5X. 
 
 
 
 
 
 
Figure S3.66. Length of the different extended segments of C18-(PEPAuM-ox)2. The total length of the extended 
molecule is ~7.5 nm. The length measurements of the peptide portion takes into account the average length spanned 
by one amino acid in both the parallel β-sheet (3.25 Å)168 and the PPII (3.1 Å)169 secondary structure. 
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Table S3.2 Detailed experimental conditions of the MAS ssNMR experiments. Abbreviations: NS, 
number of scans; Set Temp, set temperature of cooling gas; MAS, magic angle spinning rate; RD, recycle 
delay; TPPM, two-pulse phase-modulated 1H decoupling power during evolution and acquisition. 
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APPENDIX C 
SUPPORTING INFORMATION FOR CHAPTER 4: “POST-SYNTHETIC SURFACE 
MODIFICATION OF HOLLOW SPHERICAL GOLD NANOPARTICLE 
SUPERSTRUCTURES WITH TUNABLE ASSEMBLY METRICS” 
 
Figure S4.67.  TEM images of HSAuNP superstructures assembled after 10 min. with (a) 0.7 μL HAuCl4/TEAA, 
(b) 0.9 μL HAuCl4/TEAA, and (c) 1.1 μL HAuCl4/TEAA (scale bars = 100 nm). 
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APPENDIX D 
SUPPORTING INFORMATION FOR CHAPTER 5: “PEPTIDE-OLIGONUCLEOTIDE 
CHIMERAS (POCS): PROGRAMMABLE BIOMOLECULAR CONSTRUCTS FOR 
THE ASSEMBLY OF MOPHOLOGICALLY-TUNABLE SOFT MATERIALS” 
 
 
 
 
Figure S5.68. Structure of the (a) 18-base azido-modified oligonucleotide (O18-N3) and (b) 6-base azido-modified 
oligonucleotide (O6-N3). 
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Figure S5.69. Chemical structure of the azido-modified peptide (N3-C4H8CO-AAAYSSGAPPMPPF). 
 
 
 
 
 
Figure S5.70. (a) Reverse-phase HPLC trace and (b) MALDI spectrum of PO18C. (c) Reverse-phase HPLC trace 
and (d) MALDI spectrum of PO6C. Note: m/1 and m/2 peaks were observed in the MALDI spectra. 
 
 
 
 141 
 
Figure S5.71. TEM images of 500 μM PO18C in 50 mM CaCl2 after 15-20 hrs. Spherical assemblies were observed. 
 
 
 
Figure S5.72. TEM images of 500 μM PO18C in 150 mM CaCl2 after 15-20 hrs. Spherical/pseudo-spherical 
assemblies were the major products. Few fiber assemblies were also observed. 
 
 
 
 
Figure S5.73. TEM images of 500 μM PO18C in 300 mM CaCl2 after 15-20 hrs. Fibers were observed. 
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Figure S5.74. AFM images of PO18C vesicles deposited on APTES-functionalized mica. The labeled vesicles and 
their corresponding height traces are shown. In general, larger vesicles appear to flatten more than smaller vesicles. 
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Figure S5.75. Phase image of PO18C vesicles revealing the different deformation response between the sphere edge 
and sphere center. 
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Figure S5.76. AFM image of vesicles on a TEM grid after exposure to the high-vacuum TEM environment. Labeled 
vesicles and their corresponding height traces reveal a height of approximately 30 nm. A majority of the vesicles 
appear to flatten completely, except for a few that retained more of its shape (e.g., spheres 6 and 10). 
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Figure S5.77. PO18C length. The length of the extended 18mer oligonucleotide was reported to be 7.7 nm.170-171 
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Figure S5.78. Additional TEM images of gold nanoparticle-decorated PO18C vesicles after 2 hrs of incubation. 
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Figure S5.79. TEM image of 500 μM PO6C in 10 mM CaCl2 after 15-20 hrs. Fibers, aggregates, and spherical 
assemblies were observed. 
 
 
 
Figure S5.80. TEM image of 500 μM PO6C in 50 mM CaCl2 after 15-20 hrs. Fibers were observed. 
 
 
 
Figure S5.81. TEM image of 500 μM PO6C in 150 mM CaCl2 after 15-20 hrs. Fibers and fiber networks were 
observed. 
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Figure S5.82. TEM image of 500 μM PO6C in 300 mM CaCl2 after 15-20 hrs. Fibers and fiber networks were 
observed. 
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Figure S5.83. PO6C assemblies assembled in (a) 50 mM CaCl2 and (b) 10 mM CaCl2. (c-e) Zoomed-in TEM images 
of the dashed boxes shown in b (the border colors correspond to the colors of the dashed boxes). 
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Figure S5.84. (a,b) TEM images 2 hrs. after addition of 5 nm gold nanoparticles (functionalized with 
complementary 6mer sequence) to a solution containing PO6C fibers in 50 mM CaCl2. (c) UV-Vis spectrum of free 
5 nm gold nanoparticles functionalized with complementary 6mer sequence (black line) and 2 hrs. after addition to 
PO6C fibers (red line). The position of the LSPR band remains unchanged. The difference in signal intensity is due 
to different solution concentrations of gold nanoparticles. 
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Figure S5.85. PO18C (500 μM) assembled in the (a,b) absence of complement and in the (c,d) presence of 
complement. Both experiments were conducted in 150 mM CaCl2. 
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